Document:

exhibit47.htm - Generated by SEC Publisher for SEC Filing

Table of Contents

 

Exhibit 4.07 

 

 

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as "[*]". A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

 

naphtha Purchase and sale agreement entered into by, on one side, PETRÓLEO BRASILEIRO S.A. – PETROBRAS, and on the other side, by Braskem S.A., in the form below:

PETRÓLEO BRASILEIRO S.A. - PETROBRAS, a mixed-capital company, with main offices at Avenida República do Chile, No. 65, in the city and State of Rio de Janeiro, enrolled in the corporate taxpayer registry under No. 33.000.167/0001-01, herein referred to as PETROBRAS, hereby represented by its Executive Manager of Supply – Marketing and Commercialization, José Raimundo Brandão Pereira, and BRASKEM S.A., with main offices at Avenida Nações Unidas, No. 8501, in the city and State of São Paulo, enrolled in the corporate taxpayer registry under No. 42.150.391/0001-70, herein referred to as BRASKEM, hereby represented by Bernardo Afonso de Almeida Gradin and Luiz de Mendonça, also referred to jointly as the PARTIES  and individually as the PARTY. 

Considering that:

·                     PETROBRAS  is the largest producer of naphtha in Brazil and BRASKEM  is the largest consumer of naphtha in Brazil;

·                     PETROBRAS  and BRASKEM  have maintained a continuous commercial relationship since the founding of the companies that currently compose BRASKEM; 

·                     PETROBRAS  and BRASKEM  operate in industrial sectors that require long-term planning, and the presence of a lasting contractual relationship between the PARTIES  is fundamental for the sustainability and development of their businesses;

·                     the Parties  are interested in developing a relationship that expands the existing synergies between them;

·                     PETROBRAS, through the Landulpho Alves–Mataripe Refinery, herein referred to as RLAM, has a system integrated with Braskem’s  industrial units in the State of Bahia, which has had a commercial relationship with the PARTIES  for approximately 30 years;

·                     PETROBRAS, through the Alberto Pasqualini Refinery – REFAP S.A., herein referred to as REFAP, has a system integrated with Braskem’s  industrial units in the State of Rio Grande do Sul, which has had a commercial relationship through the PARTIES  for approximately 30 years.

The Parties  have mutually agreed to enter into this Purchase and Sale Agreement, which is governed by the following clauses and conditions:

 

 

First Clause — Purpose

1.1.         PETROBRAS  is obligated to sell and deliver to Braskem, and Braskem  is obligated to sell and receive from Petrobras, during the period established in Clause Nine, naphtha petrochemicals, herein referred to as “naphtha” or “product,” in the quantity described in Clause Two and at the quality described in Clause Three, in accordance with the terms and conditions stipulated in this Agreement and in Annexes I, II, and III.

1.2.         Braskem  undertakes not to sell, assign or, in any form, transfer to a third-party naphtha acquired from Petrobras, except by prior agreement between the Parties, and its use is limited to input for its pyrolysis units and/or catalytic reforming, for the purpose of producing petrochemicals.

Second Clause — Quantity 

2.1.         The maximum quantity of naphtha that Petrobras  undertakes to sell and deliver to Braskem, and that Braskem  undertakes to purchase and receive from Petrobras, is 418,300 tons.

2.1.1.      In 2010 the Parties will reassess, considering possible advances in the production of naphtha by Petrobras in Brazil, the viability of increasing the maximum monthly quantity effective from January 1, 2011.

2.1.2.      The basic quantity of naphtha to be delivered by Petrobras  at the point of delivery of Braskem’s  units in the State of Bahia, herein referred to as UNIB–BA, is 257,000 tons monthly and at the point of delivery of Braskem’s  units in the State of Rio Grande do Sul, herein referred to as UNIB–RS, is 161,300 tons monthly.

2.1.3.      Petrobras  guarantees the monthly delivery of 110,000 (one hundred ten thousand) tons of a specific type of naphthenic naphtha to UNIB-BA, except for months in which there is a scheduled downtime for the Reform Unit of BRaskem  or the Distillation Unit of RLAM and amounts of paraffinic naphtha that exceed this quantity, in accordance with the specifications presented in Annex I—Quality Specifications.

—The establishment of the Hard Order

2.2.         By the 1st (first) working day of the month (N-2), Braskem  will inform, in writing and in compliance with the minimum and maximum limits provisioned in the table below and the total maximum limit provisioned in item 2.1, the monthly quantities of naphtha that it intends to acquire from Petrobras  in the second subsequent month (N) and in the other five months after this (N+1 to N+5), indicating locations for delivery.

	

   Point of Delivery
	

   Minimum

   (ton/month)
	

   Maximum

   (ton/month)

	

   UNIB-BA
	

   110,000
	

   297,000

	

   UNIB-RS
	

   65,000
	

   201,300

2.2.1.      Braskem  may, until the 1st (first) working day of the month (N-1), request a change for a point of delivery at the maximum of 40 (forty) thousand tons of the Hard Order, such as defined in item 2.3, respecting the limits of item 2.2 above.

2

 

 

 

2.3.         By the 1st (first) working day of the month (N-1), Braskem  will confirm, in writing and respecting the minimum and maximum limits provisioned in the table of item 2.2. and the total maximum limit provisioned in item 2.1., the quantity of naphtha that it intends to acquire from Petrobras  for the subsequent month (N), separated by point of delivery, which will present a maximum variation of more or less than 10% (ten percent) in relation to the purchase order for this same month (N) stated in the previous month (N-2).

2.3.1.      The quantity confirmed will be considered the Hard Order for the subsequent month (N), becoming an obligation to deliver by Petrobras  and to receive by Braskem. 

2.3.2.      If Braskem  does not send confirmation or does so after the deadline, the Hard Order to be adopted for the subsequent month (N) will be the quantity previously informed in the previous month (N-2).

—Requests for additional quantities

2.4.         Braskem  may request, at any time, the supply of additional quantities to the Hard Order, falling to Petrobras  to confirm the possibility of additional supplies in the maximum period of 7 (seven) days, from when the request was made by BRaskem. 

2.4.1.      Additional quantities accepted by Petrobras  will be incorporated into the Hard Order of the month in question, in which case the maximum limits provisioned in items 2.1. and 2.2 will not be applicable.

—Anticipated quantities

2.5.         Parties  may agree to the supply of quantities superior to the Hard Order in respect of anticipation of the subsequent month (N+1), which will be subject to the effective price in that month (N+1).

2.5.1.      If the referred to price for the month (N+1) has not yet been determined by applying the formula established in Clause Six, the Parties  will define, mutually, the business terms for provisional billing of anticipated amounts.

2.6.         The quantities effectively provided as an advance will be deducted from the Hard Order agreed to for the next month and, as soon as the correct price is known, credit or supplementary notes will be issued in order to correct the provisional billing.

—Quantities not delivered or not received

2.7.         At the end of each month the balance between the Hard Order and quantity actually provided will be assessed. 

2.7.1.      The calculation of the amount actually provided will include the naphtha acquired by Braskem  together with Alberto Pasqualini Refinery – REFAP S.A.

2.7.1.1.      At the end of each month, Braskem  must send to Petrobras  a report that proves the effective amount of product that has been sold and delivered by REFAP, which shall be deducted from the total quantity to be delivered by Petrobras. 

 

3

 

 

 

2.8.         In the event of a balance higher than 5% (five percent) of the Hard Order, the following procedures will be adopted:

2.8.1.      Balances that Petrobras  is responsible for, except for those resulting from Unforeseeable Circumstances or Force Majeure, pursuant to Clause Ten, or scheduled downtime for maintenance of the refinery greater than 5 (five) days and previously informed pursuant to Clause Five, may be incorporated, at the choice of Braskem, to the Hard Order of the subsequent month and will be billed at the effective price of the month incurring the balance (N) or the subsequent month (N+1), whichever is lower.

2.8.2.      Balances that Braskem  is responsible for, except for those resulting from Unforeseeable Circumstances or Force Majeure, pursuant to Clause Ten, or scheduled downtime for maintenance of the refinery greater than 5 (five) days and previously informed pursuant to Clause Five, may be incorporated, at the choice of Petrobras, to the Hard Order of the subsequent month and will be billed at the higher effective price of the month incurring the balance (N) or the subsequent month (N+1), whichever is higher.

2.9.         In the event of balances being equal or below 5% (five percent) of the Hard Order, such balance will be automatically cancelled without burden or penalty to the Parties. 

Third Clause—Quality and Inspection

3.1.         The naphtha to be provided by Petrobras  must meet the quality specifications contained in Annex I of this Agreement.

3.1.1.      Petrobras  guarantees the quality of the product to the defined location for each type of sale.

3.2.         Petrobras  will make available to Braskem, prior to the start of delivery of each batch of product or unloading of vessels at the Aratu or Tramandai Terminals, a Test Certificate containing the results of quality specifications.

3.2.1.      In the event of one more results not meeting the agreed-upon quality specifications, the batch of product may only be delivered with the written consent of Braskem. 

3.2.1.1.      Acceptance by Braskem  of the specific quantity of product outside the specifications does not imply, under any circumstance, a change to the specifications or the obligation to accept other quantities in this condition.

3.2.1.2.      If Braskem  accepts receipt of a batch of product outside of the specifications and utilizes it in industrial processes, Petrobras  will be exempt from any liability for damages, direct or indirect, or lost profits that occur to Braskem  and/or other consumers supplied by it, due to the use of this product.

3.2.1.2.1.      Regardless of the above subsection, the Parties  may negotiate, prior to supplying the batch of product in question, business terms and responsibility for direct damages.

3.2.1.3.      If Braskem  does not accept receipt of any batch of product outside of specifications, the delivery of this batch will be interrupted pursuant to instructions from Braskem, and Petrobras  will keep Braskem  informed of the actions and expectations for the prompt restoration of normal supply, in accordance with the provisions of items 2.7. to 2.9.

 

4

 

 

 

 

3.2.2.      In the event of Braskem  finding a discrepancy between the results presented in the Test Certificate and the quality of the product received, a formal complaint must be sent, within a maximum period of 2 (two) working days after receipt, to Petrobras  so it may carry out the necessary investigations.  In this event, the continuation of supply of product may only occur with the written consent of Braskem. 

3.2.2.1.      Upon the finding of any non-conformity in the quality of the product, Petrobras  will be responsible for any proven, direct damages, up to the limit provisioned in the Thirteenth Clause, except for indirect damages and lost profits of Braskem  and/or other consumers supplied by it, due to the use of this product.

3.2.2.1.1.      Regardless of the provision in the sub-item above, the Parties  may negotiate conditions of liability for direct damages specific to each event.

3.2.2.2.      In the absence of agreement between the Parties  as to differences in relation to the guaranteed quality specifications of the product, a sample of the product will be submitted for review by an Independent Inspection Company, mutually agreed to by the Parties, whose report will be irrevocably accepted, and the costs will be incurred by the Party  found to be in error.

—Appointment of the Independent Inspection Company

3.3.         When it is in the interest of the Parties, an independent Inspection Company, mutually agreed to by the Parties, may be nominated to witness the certification of quality and quantity of the product sent by Petrobras  or received by Braskem, depending on the type of sale.  The costs and fees related to the hiring of such Independent Inspection Company will be equally shared between the Parties. 

3.3.1.      The independent inspector must determine the quality and quantity of the product from sampling and analyzing the product in the presence of representatives of the Parties, at the point of transfer of the product, in accordance with the type of sale as defined in this Agreement, before starting loading, unloading or pumping operations.  The inspector must retain samples for a minimum period of 90 (ninety) days after the end of the operation.

3.3.2.      The results of the quantity and quality of the product, determined by the independent inspector, will be considered definitive by the Parties, except for manifest error or fraud, and will serve as the basis for issuing documentation related to the remittance of the product and its billing.

Clause four—Operational proceedings

4.1.         For the purposes of this Agreement various types of trade will be practiced:  “Delivery at Point A” (EXA); “Free to Warehouse” (LPA) or “Deliver to Aratu or Tramandai” (EEA), descriptions of which can be found in Annex II.

 

5

 

 

 

 

4.1.1.      The PArties  may agree to, by means of Amendment, other business terms from those described in this Agreement.

4.2.         The Parties  agree that the operational procedures, such as measuring, transference of property, schedule of delivery, shortages and surpluses, among others, will be defined in Annex II.

Clause Five—Scheduled Downtime for Maintenance

5.1.         Braskem  will notify Petrobras, at least 6 (six) months in advance, of its schedule for general maintenance downtime of units consuming naphtha.

5.2.         Petrobras  will notify Braskem, at least 6 (six) months in advance, of its schedule for general maintenance downtime of its operational units interfering with compliance with this Agreement.

Clause Six—Price

6.1.      The price of naphtha will be calculated by the following formula:

Naphtha = ([*] x Ethylene  + [*] x Propylene  + [*] x Benzene  + [*] x ARA + [*] x Marlim) x Forex

Ket                           Kpr                        Kbz

Wherein:

Naphtha:          monthly price of sales of naphtha, during the month (N) in which billing occurs, in R$/t, paid in full and free from any taxes or tariffs.

Ethylene:         quarterly contract price from the Northwestern Europe ethylene market (Ethylene CP NEW), published by the ICIS, in Euros, converted to US$/t with the exchange rate published by the Central Bank of Brazil.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*].

Propylene:       monthly contract price of the polymer-grade propylene in the U.S. Gulf market (Propylene GP USG), published by the ICIS, in US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*].

Benzene:         daily spot price of benzene in the U.S. Gulf market (Benzene SP USG), published by Platts, multiplied by a factor of 3.01308 in order to transform US$ cents/gallon to US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*].

ARA:                daily average price of Physical Naphtha on the Northwestern Europe market (NWE CIF ARA), published by Platts, in US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

Marlim:             daily quotation of Marlim petroleum, published by Platts, multiplied by a factor of 6.72 in order to convert US$/bbl to US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

 

6

 

 

 

 

KET                   Ethylene CP NWE / naphtha ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Ethylene CP NWE over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

KPR                   Propylene  CP USG / naphtha ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Propylene CP USG over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

KBZ                   Benzene SP USG / nafta ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Benzene SP USG over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

Forex:              average daily prices for the sale of U.S. dollars released by the Central Bank of Brazil, in the period between the first and last day of the month (N-1).

6.1.2.      In the event of temporary unavailability or permanent discontinuation of quotation disclosure from Platts and/or ICIS or if they cease to be indicators that best reflect prices in the region, a new reference source, mutually agreed to by the parties, will be used.

6.2.         The naphtha selling price, calculated by the formula in item 6.1, to be applied in the month (N) must comply with the following limits:

6.2.1.      If the value resulting from the formula, in US$/t, before conversion into R$/t, is higher than [*] times the [*] average quotations of Physical Naphtha (NEW CIF ARA) over the previous [*], the naphtha selling price, in US$/t, will be equal to [*] times the [*] average quotations of Physical Naphtha (NEW CIF ARA) over the last [*].

6.2.2.      If the value resulting from the formula, in US$/t, before conversion into R$/t, is less than [*] times the [*] average quotations of Physical Naphtha (NEW CIF ARA) over the previous [*], the naphtha selling price, in US$/t, will be equal to [*] times the [*] average quotations of Physical Naphtha (NEW CIF ARA) over the last [*].

6.3.         ANNEX III—Pricing  illustrates the steps to calculate the monthly selling price of naphtha.

6.4.         The selling price of paraffinic naphtha, determined in accordance with the formula and conditions described in items 6.1 and 6.2, will be adjusted in accordance with its quality, based on paraffinicity, by volume.

6.4.1.      The selling price of paraffinic naphtha is to be increased by US$[*]/t per percentage point of paraffin content above [*]% and reduced by US$[*]/t per percentage point of paraffin content below [*]%.  For the interval between [*]% and [*]% there will be no accrual or discount.

6.5.         The selling price of naphthenic naphtha, determined in accordance with the formula and conditions described in items 6.1 and 6.2, will be adjusted in accordance with its quality, based on naphthenicity and aromaticity, by volume.

6.5.1.      The selling price of naphthenic naphtha is to be increased by US$[*]/t per percentage point of combined naphthenic  content and aromaticity above [*]% and reduced by US$[*]/t per percentage point of combined naphthenic  content and aromaticity below [*]%.  For the interval between [*]% and [*]% there will be no accrual or discount.

 

7

 

 

 

Clause seven—Taxes

7.1          Any taxes incurred or that may be created and that are owed as a result of direct or indirect supply of naphtha, as well as any effects of legislative changes that may create, terminate or modify taxes and tariffs now in force and applicable to the purpose of this contract will be the sole responsibility of each contributing party, as determined by law.

Clause eight—Credit, billing and payment

—The granting of credit

8.1          For the granting and maintaining of a credit line from Petrobras, Braskem  must present, whenever requested, statutory financial statements to permit Petrobras  to carry out analysis of its financial performance; Petrobras  guarantees the secrecy and confidentiality of such information.

8.2.         If the result of the analysis mentioned in section 8.1 so requires, Petrobras  may request additional guarantees to support payments in regards to supplying by installment.

8.3.         If Braskem  does not provide the additional guarantees requested in 15 (fifteen) days from the request of Petrobras, Petrobras  may decide to not concede, suspend the credit line or restrict the limit effectively presented, through prior communication to Braskem, with a minimum advance notice of 48 (forty-eight) hours.

—Billing

8.4.         Sales will be billed based on price in full, as defined in Section Six, plus federal, state and/or municipal taxes, as required by law.

8.5.         The billing of product sold will be made in reais  per kilogram immediately after each delivery, based on the calculation of quantities ascertained at the measuring points described in item 1 of Annex II, for their respective trading arrangements and the prices in effect on the dates defined below:

8.5.1.      EXA, LPA, EEA at the effective price at the end of pumping the product.

8.5.1.1.      In the event of EEA billing to be realized at the loading port, the price in effect at the end of loading will be used.

8.5.2.      The EXA type will be considered the standard method of trading, whereas the application of different modalities must occur by mutual agreement between the Parties. 

8.6.         Whenever a Credit Note is issued as a result of adjustment to sales transaction (partial cancelation), Braskem  undertakes to issue a Declaration of Non-Use of Tax Credit, in order to enable the recovery of any tax charged and/or collected in excess from Petrobras, as well as perform any act which is required for such recovery.

8.6.1.      In the event Braskem  does not issue a Declaration of Non-Use of Tax Credit, the Credit Note will be issued at a value net of all taxes.

 

8

 

 

 

 

—Payment

8.7.         If it does not have a credit limit at the time of a scheduled delivery of product, Braskem  must make deposits in an amount equal to the amount of product it intends to acquire, based on the price in effect at the time of deposit.

8.7.1.      Braskem  is obliged to present to Petrobras  proof of financial deposit, before the date provisioned for the start of supply, the carrying out of which is subject to confirmation of such deposit in the account indicated by Petrobras. 

8.7.2.      The deposit referred to in item 8.7 will not be construed as effecting payment, since the price of the product will be determined at the moment of transfer of possession and ownership of the product, pursuant to item 8.5.

8.8.         If it has a credit limit with Petrobras  at the time of a scheduled delivery of product, Braskem  may choose to pay over a certain time period or upon the presentation of the respective invoice.

—Term of payment

8.9.         The term of payment will be established between the parties, respecting the available credit limit.

8.9.1.      Under this method, the term of payment will be counted from the date of the product’s shipment contained in the invoice.

8.9.2.      The prices, taxed in accordance with the provisions of item 8.4, will accrue financing charges calculated pro rata for the agreed term of payment and based on the monthly fee previously communicated, in writing, by Petrobras. 

8.9.3.      The Parties will define, by the 20th of the month prior to supply (N-1), the term of payment for supply to be practiced in month (N).  This not being defined, the term of payment used in the previous month will prevail.

—Presentation of invoice

8.10.       If Braskem  chooses the presentation of an invoice, the term of payment will be 1 (one) day for the titles related to invoices provided by Petrobras  by 2:00 pm (two o’clock in the afternoon) of the location of billing and 2 (two) days for invoices issued after this time.

8.10.1.    Under this method, the term of payment will be counted from the date the invoice issued.

8.10.2.    The prices, taxed in accordance with the provisions of item 8.4, will accrue financing charges calculated pro rata for a period of 2 (two) days and based on the monthly fee previously communicated, in writing, by Petrobras. 

—Default

8.11.       In the event of default by Braskem  concerning the settlement of invoices, Petrobras  will have the right to adopt the methods described below, in addition to reasonable legal fees.

 

9

 

 

 

 

8.11.1     Delayed payments, not previously agreed to, are subject to arrears charges in effect for the respective month, considering the period between the date of maturity and date of payment, calculated pro rata. 

8.11.2.    Any delay in payment by Braskem, not previously agreed to, confers to Petrobras  the right to suspend the supply of product until settled or the credit limit of Braskem. 

8.12.       Factoring and/or the transfer, from Braksem  to any third-party, of cash sales slips or other payment documents issued by Petrobras  is strictly forbidden, if for the payment of product purchased.

Clause nine—term

9.1.         The term of this agreement is 5 (five) years, from March 1, 2009, being considered tacitly renewed for a single period of 5 (five) more years if neither Party  formally, in writing, declares the contrary within at least 1 (one) year prior to the end of the term of this Agreement.

9.2.         The termination of this agreement, in and of itself, will not extinguish pending rights and obligations, or make ineffective the Jurisdiction or Secrecy and Confidentiality Clauses, which will continue to be in effect for the periods established herein or provided by law.

Clause Ten—unforeseeable circumstances and force majeure

10.1.       The Parties will not be liable for the breach of obligations or losses arising from unforeseeable circumstances or force majeure, pursuant to Article 393 of the Brazilian Civil Code, in which case either of the Parties may rely upon contractual resolution of the agreement.

10.2.       In the event of interruptions in the delivery and pickup periods arising from events characterized by unforeseeable circumstances or force majeure, the term of the agreement will be extended.

10.3.       Upon the occurrence of circumstances that justify the invocation of the existence of unforeseeable circumstances or force majeure, the PArty  that is unable to fulfill its obligations must immediately inform the other, in writing, of the occurrence and its consequences.

10.4.       Upon the occurrence of circumstances that justify the invocation of the existence of unforeseeable circumstances or force majeure, the Parties  will independently cover their respective losses.

10.5.       If the reason for delay or its cause lasts for more than ninety (90) consecutive days, any one of the parties  may notify the other, in writing, of the termination of this Agreement, under the same conditions stipulated in item 10.4 above.

Clause Eleven—excessive burden, economic-financial imbalance of the agreement and exception of the agreement not fullfilled

11.1.       In case of a supervening and unpredictable situation causign excessively burdensome conditions for one of the PARTIES, the aggrieved PARTY may request termination of this Agreement. However, the PARTIES  may maintain this Agreement in effect should they reach an agreement upon negotiation with regard to revision of the contractual conditions or provisions for performance thereof.

 

10

 

 

 

11.2.       In case of a supervening, extraordinary and unpredictable fact affecting the original economic and financial contractual conditions hereof, the PARTIES shall renegotiate their conditions in order to return to the original contractual balance, taking into consideration the evidence submitted by the PARTIES. 

11.3.       After the Agreement is signed, if a PARTY  incurs a decrease in its equity, capable of jeopardizing or rendering the provision to which it was bound doubtful, the other party may refuse to observe the provision dependent thereon, until the former takes the required steps to rectify the situation or offer sufficient guarantee that it shall rectify it.

Clause twelve—Termination

12.1.       Any of the parties may terminate this Agreement under the following situations:

12.1.1.    When after being notified for nonperformance of any of the Clauses or conditions herein, the defaulting PARTY  fails to adopt within a thirty (30) days’ term from the notice, the necessary measures for correction of the violation committed;

12.1.2.    Bankruptcy, judicial or extrajudicial liquidation, decreed or ratified, of any Party; 

12.1.3.    Assignment or transfer in whole or in part without prior written consent of the other PARTY of the rights and obligations attributed herein, except in the case of a company belonging to the same economic group;

12.1.4.    Assignment or the offer to guarantee in whole or in part of any credits related to or originating from this Agreement, except in the event of prior written consent of the other PARTY; 

12.1.5.    Occurrence of a proven event of force majeure or unforeseeable circumstance that hinders the continuation of this Agreement, pursuant to item 10.5; 

12.1.6.    Dissolution of the corporate structure of any of the PARTIES; 

12.1.7.    Change in the corporate structure or change of the company’s purpose that may conflict with the subject matter hereof;

12.1.8.    Ratification of any extrajudicial reorganization plan or the granting of judicial reorganization, if BRASKEM  fails to provide sufficient bond to guarantee the performance of the contractual obligations, at the discretion of PETROBRAS. 

12.2.       Instead of terminating this Agreement, after the term referred to in sub-item 12.1.1 has elapsed, the aggrieved PARTY  may suspend its performance for the term it deems necessary, so that the defaulting PARTY  remedies the contractual Clause(s) violated.

12.3.       Any forbearance with regard to nonperformance by the PARTIES of the obligations, conditions and terms set out herein shall not entail an amendment to or novation of the provisions agreed on herein.

 

11

 

 

 

 

12.4        Should the Agreement be terminated, the defaulting PARTY  shall be held liable under the law and the agreement for violation or improper performance hereof and which has caused such termination.

Clause thirteen—liabilities

13.1.       The liability of Parties for losses and damages will be limited to direct damages in accordance with the Brazilian Civil Code and applicable laws, excluding indirect damages and lost profits, proven direct damages being limited to, per event, 30% (thirty percent) of the value of supplied product over the last 12 (twelve) months prior to the date in which the damage had occurred.

13.1.1.    In the of event of direct damages caused in the first 12 (twelve) of this agreement, the liability limit referred to in the previous item will be calculated on the basis of the monthly average already billed multiplied by 12 (twelve).

13.1.2.    The PARTIES shall be ensured a right of recourse in case one of them is required to redress under article 927, sole paragraph of the Brazilian Civil Code any damage caused by the other PARTY to third parties, and in such event, the cap set out in the item above shall not apply.

13.1.3.    The amounts actually obtained by a third party in or out-of-court shall be subject to recourse, in addition to all expenditures involved, such as court costs, fees of counsel, extrajudicial costs, etc.

Clause fourteen—assingment

14.1 .      This Agreement may not be assigned in whole or in part by the PARTIES, without prior written consent of the other PARTY, and it shall be binding on their successors as regards the performance of the obligations.

Clause fifteen—secrecy and confidentiality

15.1.       The terms of this Agreement and all information disclosed by virtue of the terms contained herein, except for inquiries of their existence, shall be afforded confidential treatment and such confidentiality shall last for 5 (five) years after termination of the Agreement.

15.2.       Nonperformance of the confidentiality and secrecy obligation shall entail:

a)            the Termination of this Agreement, if in effect;

b)            in any event, liability for losses and damages; and

c)            adoption of legal remedies and applicable sanctions under Law 1,355/94, its annexes and other applicable laws.

15.3.       As reasons for exception to the obligation of confidentiality, only the occurrence of the following events of nonperformance shall be deemed legitimate:

a)            The information already known prior to the arrangements for contracting, irrespective of it being direct or through a legal proceeding;

 

 

12

 

 

 

b)            There was prior and express consent of PETROBRAS and BRASKEM, upon authorization of the most important body in charge of the Agreement of both PARTIES, as to the release of the obligation of confidentiality and secrecy;

c)            The information was proved to be obtained by another source legally and lawfully, irrespective of the Agreement;

d)            Judicial or government order for cognizance of the information, provided that notified forthwith to PETROBRAS or BRASKEM, prior to the release, and upon request of court secrecy in the judicial and/or administrative handling thereof.

CLAUSE SIXTEEN—REPRESENTATIONS OF THE PARTIES

The PARTIES  hereby represent that:

16.1.       they are cognizant of the rules contained in article 157 of the Brazilian Civil Code, and no fact or obligation that may be typified as an injury is present in this contracting;

16.2.       the obligations assumed are hereby acknowledged by both parties as manifestly proportional;

16.3.       the proportionality of the provisions assumed ensue from amounts in effect at the time that this Agreement was executed;

16.4.       they are cognizant of the circumstances and rules guiding this legal agreement and have experience in the activities attributed thereto under this Agreement;

16.5.       they exercise their freedom to contract, with due regard for the precepts of public order and the principle of social role of this Agreement, which also meets the principle of economy, reasonableness and opportunity, thus enabling attainment of the corresponding corporate purposes by the PARTIES and corporate activities, and consequently serving the entire society;

16.6.       they shall always observe the principles of good faith and honesty in the performance of this Agreement, which shall also be present in the negotiation and in the execution hereof;

16.7.       this Agreement is signed upon strict observance of the principles set out in the preceding sub-items, and in no event shall it permit abuses of the rights contained herein;

16.8.       In case of annulment of any provision hereof, the remaining contractual provisions shall be valid and so the validity of the legal agreement signed herein shall not be affected in its general terms;

16.9.       Upon its signature, this Agreement shall prevail, thus replacing any arrangements whether in writing or orally previously held between the PARTIES with regard to the purpose hereof.

16.10.     The PARTIES undertake to maintain the policy on Industrial Safety, Environment and Occupational Health consistent with the legal rules in effect in Brazil, as well as to maintain a conduct consistent with the principles of social responsibility.

 

13

 

 

 

 

Clause seveenteen—general provisions

17.1 . The following EXHIBITS are integral parts hereof:

Annex I—Technical Specifications

Annex II—Operational Procedures

Annex III—Price Calculation

17.2.       In case of conflict between the terms of this Agreement and its exhibits, the provisions of this Agreement shall always prevail.

17.3.       Any amendment in any way to the terms hereof, also by reason of supervening facts or opportunities imposing review of the preliminary provisions shall only be formalized upon a written amendment.

17.4.       The PARTIES undertake to exert their best efforts to address any events not contemplated hereby through direct understandings between them by mutual agreement, based upon the analogy, habits and general principles of business.

17.5.       The correspondence referring to this Agreement, including place of payment, shall be sent to the addresses stated below, and the Contracting Parties are entitled to state other addresses in writing:

Petróleo Brasileiro S.A. - PETROBRAS

Gerência de Comércio de Nafta e Matérias Primas Industriais

Av. República do Chile, 65 _190 andar, sala 1901

CEP 20031-912 Rio de Janeiro-RJ

Email: materiasprimas@petrobras.com.br

BRASKEM S.A.

Rua Eteno, 1561, Pólo Petroquímico de Camaçari

CEP 42810-00

Camaçari - BA - Brasil

FAX: (71) 3413-2098

Email: materiasprimas@braskem.com.br

17.6.       In the event of dates linked to this Agreement or its Annexes occurring on weekends or holidays, these dates will be postponed to the following business day.

17.7.       From the date of this agreement entering into force, the PARTIES agree to terminate the Raw Material Supply Agreement entered on February 23, 1996, between PETROBRAS and COPESUL – Companhia Petroquímica do Sul, and the Parties must reciprocally fulfill all obligations outstanding on that date, originating from such Agreement.

CLÁUSULA DÉCIMA OITAVA - FORO

18.1.       The Central Court in the Judicial District of the Capital of the State of Rio de Janeiro is hereby elected to settle any issues arising out of the performance hereof, with the exclusion of any other court, however appropriate it may otherwise be.

 

14

 

 

 

 

 

IN WITNESS WHEREOF, the PARTIES sign this Naphtha Purchase and Sale Agreement, jointly with the witnesses below, in 2 (two) counterparts of equal content and form, for one sole effect.

Rio de Janeiro, July 24, 2009.

                     /s/José Raimundo Brandão Pereira                    
José Raimundo Brandão Pereira 
Executive Manager of Supply – Marketing and Sales 
PETRÓLEO BRASILEIRO S.A. – PETROBRAS

                     /s/Bernardo Afonso de Almeida Gradin                     
Bernardo Afonso de Almeida Gradin  
Chief Executive Officer 
BRASKEM S.A.

                      /s/Luiz de Mendonça                     
Luiz de Mendonça 
Director 
BRASKEM S.A.

Witnesses:

	

   /s/Hardi Luiz Schuck             
Name: Hardi Luiz Schuck 

	

   /s/Guilherme Pontes Galvão França              
Name: Guilherme Pontes Galvão França 

 

15

 

 

 

 

Annex I—Technical Specifications

1. Paraffinic Naphtha

	

   Characteristics
	

   Unit
	

   Method
	

   Specification

	

   Density 20/4°C
	

   —
	

   ASTM-D-4052
	

   0.66 -0.72

	

   PID
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   5%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   10%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   20%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   30%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   50%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   70%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   90%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   95%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   PFD
	

   °C
	

   ASTM-D-86
	

   190 max

	

   Distillation residue
	

   %Vol
	

   ASTM-D-86
	

   1.5 max

	

   Cor
	

   Saybolt
	

   ASTM-D-156
	

   20 min

	

   Vapor Pressure (PVR)
	

   psi
	

   ASTM-D-323
	

   12.5 max

	

   Sulfur
	

   ppmm
	

   ASTM-D-4045
	

   400 max

	

   Iron
	

   ppbm
	

   UOP-350
	

   300 max

	

   Lead
	

   ppbm
	

   UOP-350
	

   20 max

	

   Copper
	

   ppbm
	

   UOP-350
	

   10 rnax

	

   H2S
	

   ppmm
	

   UOP-163
	

   10 max

	

   Total Chloride
	

   ppmm
	

   ASTM-D-5808
	

   5 max

	

   Total Paraffinicity(1) 
	

   %vol
	

   ASTM-D-5134
	

   65 min

	

   N-Paraffinicity( 
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   l-Paraffinicity( 
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Olefins
	

   %vol
	

   ASTM-D-5134
	

   1 max

	

   Naphthenics
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Mehtanol
	

   ppm
	

   CONTEC-n-2448
	

   10 max

	

   Ethanol
	

   ppmm
	

   CONTEC-n-2448
	

   100 max

	

   MTBE
	

   ppmm
	

    
	

   60 max

	

   CS2(2)
	

   ppmm
	

   ASTM-D-5504
	

   7 max

	

   Mercury(3)
	

   ppbm
	

   —
	

   —

(1)           Braskem maynot refuse to receive naphtha with paraffinicity below the minimum specification due to the price adjustment set forth in item 6.4 of this Agreement.

(2)           Due to the current inability to verify this parameter in the laboratories of Petrobras, the Parties will agree to a minimum period for this item to come to be included in technical specifications.

The Parties agree to control the specification of CS2 based on the moving average weighted by the quantity of each batch over the last 30 (thirty) days of supply, establishing a maximum average value of 7 (seven) ppm as a limit, the maximum limit for individual batches being 15 (fifteen) ppm.  If the moving average for the last 30 (thirty) days exceeds 7 (seven) ppm, the maximum unit per batch will come to be 10 (ten) ppm.

The CS2 specification will only be applied to naphtha delivered to UNIB-BA.  The Parties  agree to include the CS2 specification to naphtha delivered to UNIB-RS and assess its limits if Braskem  verifies the occurrence of a problem related to this item.

 

16

 

 

 

 

(3)           The Parties will both monitor, based on analysis carried out by Braskem, the mercury content of naphtha supplied by Petrobras.  If it’s verified that monthly average of mercury content in naphtha supplied by Petrobras exceeds the limit of 5 ppb, the Parties will define by mutual agreement the inclusion of this technical quality specification item.

 

17

 

 

 

 

2. Naphthenic Naphtha

	

   Characteristics
	

   Unit
	

   Method
	

   Specification

	

   Density 20/4°C
	

   —
	

   ASTM-D-4052
	

   0.66 -0.72

	

   PID
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   5%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   10%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   20%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   30%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   50%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   70%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   90%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   95%
	

   °C
	

   ASTM-D-86
	

   Annotate

	

   PFD
	

   °C
	

   ASTM-D-86
	

   190 max

	

   Distillation residue
	

   %Vol
	

   ASTM-D-86
	

   1.5 max

	

   Cor
	

   Saybolt
	

   ASTM-D-156
	

   20 min

	

   Vapor Pressure (PVR)
	

   psi
	

   ASTM-D-323
	

   12.5 max

	

   Sulfur
	

   ppmm
	

   ASTM-D-4045
	

   400 max

	

   Iron
	

   ppbm
	

   UOP-350
	

   300 max

	

   Lead
	

   ppbm
	

   UOP-350
	

   20 max

	

   Copper
	

   ppbm
	

   UOP-350
	

   10 rnax

	

   H2S
	

   ppmm
	

   UOP-163
	

   10 max

	

   Total Chloride
	

   ppmm
	

   ASTM-D-5808
	

   5 max

	

   Total Paraffinicity 
	

   %vol
	

   ASTM-D-5134
	

   65 min

	

   Normal-Paraffinicity( 
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   lso-Paraffinicity( 
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Olefins
	

   %vol
	

   ASTM-D-5134
	

   1 max

	

   Naphthenics + Aromatics (1)
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Naphthenics
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Aromatics
	

   %vol
	

   ASTM-D-5134
	

   Annotate

	

   Mehtanol
	

   ppm
	

   CONTEC-n-2448
	

   10 max

	

   Ethanol
	

   ppmm
	

   CONTEC-n-2448
	

   100 max

	

   MTBE
	

   ppmm
	

    
	

   60 max

	

   CS2(2)
	

   ppmm
	

   ASTM-D-5504
	

   7 max

	

   Mercury(3)
	

   ppbm
	

   —
	

   —

(1)           Braskem maynot refuse to receive naphtha with the sum content of naphthenics and aromatics below the minimum specification due to the price adjustment set forth in item 6.5 of this Agreement.

(2)           Due to the current inability to verify this parameter in the laboratories of Petrobras, the Parties will agree to a minimum period for this item to come to be included in technical specifications.

The Parties  agree to control the specification of CS2 based on the moving average weighted by the quantity of each batch over the last 30 (thirty) days of supply, establishing a maximum average value of 7 (seven) ppm as a limit, the maximum limit for individual batches being 15 (fifteen) ppm.  If the moving average for the last 30 (thirty) days exceeds 7 (seven) ppm, the maximum unit per batch will come to be 10 (ten) ppm.

The CS2 specification will only be applied to naphtha delivered to UNIB-SA.  The Parties  agree to include the CS2 specification to naphtha delivered to UNIB-RS and assess its limits if Braskem  verifies the occurrence of a problem related to this item.

 

18

 

 

 

	

   

   [W&C Draft Redaction for CTR: April 4, 2012]

   

 

(3)           The Parties will both monitor, based on analysis carried out by Braskem, the mercury content of naphtha supplied by Petrobras.  If it’s verified that monthly average of mercury content in naphtha supplied by Petrobras exceeds the limit of 5 ppb, the Parties will define by mutual agreement the inclusion of this technical quality specification item.

 

19

 

 

 

 

ANNEX II – OPERATIONAL PROCEEDINGS

1 – MODE OF COMMERCIALIZATION

1.1       To carry out the object of this Agreement shall be applied to marketing arrangements “Delivery at Point A” (Entrega no Ponto A—EXA), “Free to Store” (Livre para Armazém—LPA), or “Delivery at Aratu Tramandai” (Entrega em Aratu ou Tramanaí—EEA), described according to the following tables:

	

   Term Identity
	

   Load Transportation

	

   Initials
	

   Name
	

   Description
	

   Mode of Transportation
	

   Freight Payment or Transportation Tariff
	

   Boarding
	

   Insurance
	

   Landing

	

   EXA
	

   Delivery at point A
	

   Braskem assumes the risks and expenses from point “A” on of the Petrobras supply unit (terminal ou refinery). The quality warranty ceases at point “A.”
	

   Pipeline
	

   Place of origin
	

   At point “A”
	

   At point “A”
	

   At point “A”

	

   LPA
	

   Free to Store
	

   Petrobras assumes all expenses and risks until the delivery of the product in the industrial unit of Braskem. Also at this point the quality warranty ceases.
	

   Pipeline
	

   Petrobras
	

   N/A
	

   Optional
	

   N/A

	

   EEA
	

   Delivery at Aratu Tramandai
	

   Petrobras assumes all boarding expenses, risks and responsibilities until the delivery in the landing of the ship in the destination port
	

   Waterway
	

   Petrobras
	

   Petrobras
	

   Optional
	

   Petrobras

 

 

	

   Term Identity
	

   Load Transportation

	

   Initials
	

   Name
	

   Description
	

   Location of Quantity Measurement 
	

   Location of Quality Inspection
	

   Location of Quality Warranty
	

   Location of Risks and Properties Transfer
	

   Location of Ownership Transfer

	

   EXA
	

   Delivery at point A
	

   Braskem assumes the risks and expenses from point “A” on of the Petrobras supply unit (terminal ou refinery). The quality warranty finishes at point “A.”
	

   Place of origin, preferably at Petrobras EMED
	

   Place of origin
	

   At point “A”
	

   At point “A”
	

   At point “A”

	

   LPA
	

   Free to Store
	

   Petrobras assumes all expenses and risks until the delivery of the product in the industrial unit of Braskem. Also at this point the quality warranty ceases.
	

   Place of origin, preferably at Petrobras EMED
	

   Place of origin
	

   intake flange on the basis of the destination
	

   intake flange on the basis of the destination
	

   intake flange on the basis of the destination

	

   EEA
	

   Delivery at Aratu Tramandai
	

   Petrobras assumes all boarding expenses, risks and responsibilities until the delivery in the landing of the ship in the destination port
	

   Petrobras premises, preferably at EMED
	

   Petrobras premises at place of origin
	

   discharge flange of the vessel at the port of destination
	

   discharge flange of the vessel at the port of destination
	

   discharge flange of the vessel at the port of destination

 

20

 

 

 

 

 

2 – TRANSFER OF PROPERTIES AND RISKS 

 

 - Property Transfers

 

2.1.      In the EXA mode of commercialization, the transfer of product properties will occur downstream to Point “A” of the PETROBRAS supply unit.  This mode applies to the quantities transported through:

a)    Pipeline III, interconnecting Transpetro-BA to UNIB-BA in Camaçari, BA.

b)    Pipeline ORSUL 14,” interconnecting REFAP to UNIB-SR in Triunfo, RS.

 

2.2.      In the LPA mode of commercialization, the product properties transfer will occur downstream to the intake flange of the BRASKEM industrial unit. This mode applies to the quantities transported through pipeline I, interconnecting RLAM to BRASKEM industrial unit in Camaçari, BA.

 

2.3. In the EEA mode of commercialization, the product properties transfer will occur downstream to the discharge flange of the vessel in the destination port.

 

 - Risk Transfers

 

2.5.      From the properties transfer point defined for each mode of commercialization, the risks for loss of quality, quality depreciation and third party risks will be automatically transferred from PETROBRAS to BRASKEM.

 

2.6.      The environmental risks shall comply with the provisions of Brazilian Environmental Legislation.

 

3 – SUPPLY PROGRAM

 

3.1. Monthly Schedule:

 

3.1.1 Until the [*] of each month (N=-1), PETROBRAS will inform, in writing, the final schedule of vessels, with the respective quantity by naphtha type (paraffinic/naphthenic) intended for BRASKEM, provisioned to the month (N). This schedule will ensure the proportionality of diary deliveries, so that the agreed quantity in item 2.1 of the Agreement can be delivered within the month.

 

3.1.2. The sent schedule will be updated weekly and might be altered during the term by PETROBRAS, if BRASKEM’s operational continuation is guaranteed and the delivery of the quantity according to the agreed type of naphtha. There must be notice of at least 15 days between the indication of the ship, its amount and type of naphtha and estimated date of arrival. The same period must be applied for the notice of pumping by quantity and type of naphtha to be delivered by the RLAM. 

 

21

 

 

 

 

3.1.3. Any changes in scheduling may be accepted within the discretion of BRASKEM, less than 15 (fifteen) days except for REFAP production, whose forecast pump can be updated weekly, preferably on Mondays.

3.1.4. BRASKEM commits itself to inform the daily consumption preview for the 30-day period.

3.1.5. The quantity differences presented in the month will be treated in compliance with items 2.7, 2.8 and 2.9 of the Agreement.

3.2 Program to unload vessels at the Raw Material Port, in Aratu (TMP)

3.2.1 On or before the 20th of each month (N-!) BRASKEM shall present three tracks for the operation of ships in Aratu, and PETROBRAS shall choose two of the three tracks to operate its vessels.

3.2.2. The month schedule presented by PETROBRAS shall include the lots for docking in Aratu (TMP), and it is BRASKEM’s responsibility to confirm the number of vessels that can operate based on the tracks chosen by PETROBRAS.

3.2.3. The operating tracks might be altered in mutual agreement between the PARTIES.

3.2.4. BRASKEM may, at its sole discretion, charge PETROBRAS a fee for the use of TMP.

3.2.5. The maximum fee charged by BRASKEM for the operations at Aratu terminal will be [*]% ([*] percent) of the fee published by Transpetro for the operation of naphtha vessels in the Madre de Deus Terminal.

3.2.6. If it is necessary to operate the PETROBRAS vessel from the agreed tracks, BRASKEM may, at its sole discretion, charge PETROBRAS for the travel and demurrage expenses caused by program change.

3.3 Nomination of an independent inspector and determination of quantity and quality operations in TMP:

3.3.1. The PARTIES shall appoint an independent inspector, by mutually agreement, to witness the certification of quality and quantity of product received by BRASKEM. The costs and fees related to the hiring of this independent inspector shall be shared equally between the PARTIES.

3.3.2. The independent inspector should establish the amount of the product and make the collection of representative samples of product quality.

 

22

 

 

 

 

3.3.3. In the event of any discrepancy be found between the results of the amount calculated at the origin, the procedures adopted will be arranged on items 5.5 to 5.7 of Annex II.

3.3.4. In the event that BRASKEM finds any discrepancy between the results presented in the quality test certificate issued at the origin and quality of the product specified in the destination, it will apply the procedures described in section 3.2.2 of the Agreement.

4 – MEASUREMENT

 - Mode of Commercialization “Delivery at Point A” (EXA) and “Free to Store” (LPA)

4.1 The measurement of quantities of naphtha supplied to BRASKEM in modes of commercialization EXA and LPA, will be made, preferably, by the properties measuring station (EMEO) owned by PETROBRAS, based on calibrated standards from INMETRO and installed in the area of Supplier Unit of PETROBRAS

4.1.1. The final determination of quantities of products supplied by PETROBRAS will be conducted in bulk for billing purposes.

4.1.2. The verification of the quantities may be done daily by PETROBRAS and BRASKEM in their respective measurement stations or computers directly connected to the controllers of measurement stations. PETROBRAS and BRASKEM may exchange information on the quantities found, on the same day of the reading, except weekends and holidays, monitoring on a daily basis any deviation between the measurement systems.

4.1.3. The closing time of balance billing amounts provided shall be agreed between the companies.

4.1.4. To calculate the quantities through EMED, the Manual of Petroleum Measurement Standards, Chapter 12.2, Calculation of Liquid Petroleum Quantities Measured by Turbine or Displacement Meters, First Edition (ANSI / API MPMS 12.2) will be followed.

4.1.5. The calibration of the measurer used for billing EMED should be carried out by a tester.

4.1.6. PETROBRAS will be responsible for operation, maintenance and replacement of components of EMED, being allowed to access the representatives of BRASKEM to follow to the installation.

4.1.7. The calibration of the EMED measurer will be made by PETROBRAS, based on its utilization factor, the frequency observed minimum of one (1) month, always at BRASKEM notice of at least 5 (five) working days in advance, in order to enable that, if desired, to be represented for monitoring works.

 

 

23

 

 

 

4.1.8. In the absence of a representative of BRASKEM, PETROBRAS will calibrate the measurer, without BRASKEM rights to present any claims about this procedure, and PETROBRAS shall provide a copy of Calibration Report, including Meter Factor graphics.

4.1.9. BRASKEM may request extra calibration of any EMED equipment, upon notification, and if equipment is found to be adjusted, the costs of calibration are charged BRASKEM.

4.1.10. When monitoring of calibrations carried out according to the criteria of the Manual of Petroleum Measurement Standards Chapter 13: Statistical Aspects of Measuring and Sampling, Section 2 - Methods of Evaluating Meter Proving Data, American Petroleum institute, indicate the need, many calibrations additional as needed will be made, without necessarily notice to BRASKEM.

4.1.11. In any of the situations described in the previous two sub-items PETROBRAS will place the updated copy of the Report of Calibration available to BRASKEM.

4.2. In cases of proven impossibility of measuring by PETROBRAS EMED, the measurement for billing purposes shall be made based on the indications of EMED BRASKEM, provided it is calibrated based on standards traceable to INMETRO with accompanying measurements and / or calibration by the representatives of PETROBRAS.

4.2.1. To calculate the quantities through EMED will be followed the Manual of Petroleum Measurement Standards, Chapter 12.2, Calculation of Liquid Petroleum Quantities Measured by Turbine or Displacement Meters, First Edition (ANSI / API MPMS 12.2), or APL MPMS 5.6 Manual 01 Petroleum Measurement Chapter 5-Metering Standards, Section 6 - measurement of Liquid Hydrocarbons by Coriolis Meters or other chapter from the Handbook of Petroleum Measurement Standards, as the measurement principle being applied.

4.2.2. The calibration of the EMED measurer used for billing should be carried out by a tester.

4.2.3. BRASKEM is responsible for the operation, maintenance and replacement of components of EMED, being allowed access to representatives of PETROBRAS for monitoring to the installations.

4.2.4. The calibration of the EMED measurer will be made by BRASKEM, based on its utilization factor, respecting the frequency of one (1) month, always warning PETROBRAS, at least five (5) working days in advance, in order to enable it, if desired, to be represented for the monitoring works.

4.2.5. In the absence of a representative of PETROBRAS, BRASKEM will make the calibration of the measurer, without PETROBRAS right to claim on this procedure, and provide a copy to PETROBRAS of the Calibration Report, including the Meter Factor graphics.

 

24

 

 

 

 

4.2.6. PETROBRAS may request any extra calibration EMEO equipment upon notification, and if equipment is found to be adjusted, the costs of calibration are charged of PETROBRAS

4.2.7. When monitoring of calibrations carried out according to criteria of the Manual of Petroleum Measurement Standards Chapter 13: Statistical Aspects of Measuring and Sampling, Section 2 - Methods of Evaluating Meter Proving Data, American Petroleum Institute, indicate the necessity, additional calibrations shall be made, without necessarily be prior notice to BRASKEM.

4.2.8. In any of the situations described in the previous two sub-items BRASKEM will place the updated copy of the Report of Calibration available to PETROBRAS.

4.3 In cases of proven impossibility of measuring through EMEDs of PETROBRAS and BRASKEM, quantification for billing purposes shall be made based on measurements of the tanks of BRASKEM or PETROBRAS, in that order of preference, performed according to the Ordinances of the former National Institute of Weights and Measures (INPM), effective for quantitative calculation of derivatives using liquid and for calculations of quantities, the official table of the CNP (Tables Correcting densities and Volumes of Petroleum Products, Resolution 6-70, of June 25, 1970).

4.3.1. The PARTIES undertake to keep their tanks for sale in good measurement condition, with tonnage certificates issued by INMETRO, within the period of validity as well as measuring instruments (automatic level measurers radar type or automatic level measurer with servo-operated shifter , automatic temperature measurer ,measuring tape, thermometers and hydrometers) calibrated based on standards traceable to INMETRO.

4.3.2. In the case of the use of automatic level and temperature measurer, they should be properly validated by PETROBRAS or BRASKEM, as well as the tank to be used, and follow the criteria of the Manual of Petroleum Measurement Standards Chapter 3 - Tank Gauging, Section 1B - Standard Practice for Measurement of Liquid Hydrocarbons in Stationary Tanks by Automatic Tank Gauging.

4.3.3. During the dispatch operations, simultaneous operations cannot occur (lung operation) in the tank shipper, which must be segregated and isolated by block valves (preferably double-lock valve).

- Mode of Commercialization “Delivery in Aratu”

4.4. The measurement of quantities of naphtha supplied to BRASKEM, in the mode of commercialization EEA, will be made, preferably, by Measuring Station (EMED) owned by PETROBRAS, based on calibrated standards traceable to INMETRO and installed in the area of PETROBRAS Supply Unit at the loading port.

 

25

 

 

 

 

4.4.1. To calculate the quantities through EMED will be followed the Manual of Petroleum Measurement Standards, Chapter 12.2, Calculation of Liquid Petroleum Quantities Measured by Turbine or Displacement Meters, First Edition (ANSIIAPI MPMS 12.2).

4.4.2. The calibration of the EMED measurer used for billing should be performed by a tester.

4.4.3. PETROBRAS will be responsible for operation, maintenance and replacement of components EMEO, being allowed to access representatives of BRASKEM to follow, to the installations.

4.4.4. The calibration of the measurer EMED will be made by PETROBRAS, based on its utilization factor, respecting the minimum frequency of 1 (one) month, always previously noticing BRASKEM in advance of at least 5 (five) working days, in order to enable that, if desired, to be represented for monitoring works.

4.4.5. In the absence of a representative of BRASKEM, PETROBRAS will calibrate the measurer, without BRASKEM rights to present any claims about this procedure, and PETROBRAS shall provide a copy of Calibration Report, including Meter Factor graphics.

4.4.6. BRASKEM may request extra calibration of any EMEO equipment upon notification, and if equipment is found to be adjusted, the costs of calibration are charged BRASKEM.

 

4.4.7. When monitoring of calibrations carried out according to criteria of the Manual of Petroleum Measurement Standards Chapter 13: Statistical Aspects of Measuring and Sampling, Section 2 - Methods of Evaluating Meter Proving Data, American Petroleum Institute, indicate the necessity, additional calibrations shall be made, without there necessarily be a prior notice to BRASKEM.

4.4.8. In any of the situations described in the preceding two sub-items, PETROBRAS will place the updated copy of the Report of Calibration available to BRASKEM.

4.5 In the absence of EMEO or proven its failure, the determination of quantities for billing purposes shall be made based on measurements of the tanks or PETROBRAS, carried out in accordance with the Regulations of the former National Institute of Weights and Measures (INPM), effective for quantitative calculation of derivatives using liquid and for calculations of quantities, the official table of the CNP (Tables Correcting densities and Volumes of Petroleum Products, Resolution 6-70, from June 25, 1970).

4.5.1. PETROBRAS undertake to keep their tanks for sale in good measurement condition, with tonnage certificates issued by INMETRO, within the period of validity as well as measuring instruments (automatic level measurers radar type or automatic level measurer with servo-operated shifter , automatic temperature measurer ,measuring tape, thermometers and hydrometers) calibrated based on standards traceable to INMETRO.

26

 

 

 

 

 

 

4.5.2. In the case of the use of automatic level and temperature measurers, they should be properly validated by PETROBRAS and follow the criteria of the Manual of Petroleum Measurement Standards Chapter 3 - Tank Gauging, Section 18 - Standard Practice for Measurement of Liquid Hydrocarbons in Stationary Tanks by Automatic Tank Gauging.

4.5.3. During the dispatch operations, simultaneous operations cannot occur (lung operation) in the tank shipper, which must be segregated and isolated by block valves (preferably double-lock valve).

4.6. If, after completion of loading, the difference between the amount of land cleared compared to fixed by the board of the Vessel Experience Factor is outside the range (-) 0.3% (+) 0.3% all measurements should be redone and the remaining difference, the amount that will apply to income that is calculated on board at the origin, corrected by the Vessel Experience Factor.

4.7. If the ship does not carry qualifying travel to calculate the experience factor, the amount for that billing will be calculated in earth ponds of the Terminal or PETROBRAS Refinery at the ports of loading. However, if the difference land x board, in the load, exceeds 0.5%, for more or less, PETROBRAS will be triggered to analyze the trip after unloading and issue an opinion in line with his or BRASKEM representative on the amount to be billed in short, within a maximum of 10 (ten) working days after receipt of all documentation after the trip.

4.8. If, due to operational problems (lung or transfer operation), the load has to be expressed by board, the amount that will apply to income will be the one calculated on board receiver, at the origin, corrected by the Vessel Experience Factor (FEN) calculated as of API, Chapter 17.10. In this case the measuring devices must be calibrated based on the standards traceable INMETRO.

4.9. BRASKEM may send a representative to monitor and verify the measurements made in the place of loading.

5 – ABSENCES AND REMAINS

Modes of Commercialization “Delivery at Point A” (EXA) and “Free to Store” (LPA)

5.1. The monthly differences arising between the amounts provided by PETROBRAS and the amounts received by BRASKEM will be considered compliant when understood within acceptable limits established in the Manual of General Instructions - MIG PETROBRAS, calculated on the basis of quantities issued by PETROBRAS, listed below:

 

27

 

 

 

 

-Measurements in tanks compared to measurements in tanks or online measurements compared with measurements in tanks:

	

   Product
	

   Monthly (%)

	

   Naphtha
	

   -0.10 to +0.05

 

-Online measurements compared with measurements online (versus EMED EMED):

Based on the history of the last three months of the measurements of two EMEDs, when they are demonstrably calibrated and adjusted, the PARTIES will establish the maximum acceptable relative difference

5.1.1. The PARTIES shall simultaneously send information about the
quantities shipped and received, except in exceptional cases, when the matter will be handled locally

5.2. In each Point of Supply a Local Committee of Absences and Remains shall be constituted composed of local representatives of PETROBRAS and BRASKEM, which will determine, based on historical statistics of the movement of the Point of Supply, in which individual cases are not applicable limits of absences and remains from the tables of item 5.1, as well as the limits of absences and remains out of which the individual pumping will be considered nonconforming.

5.2.1. The Local Committee Absences and Remains will submit the study results, 
possible proposals for new rates obtained in item 5.2 to analyze the specialized area of ​​PETROBRAS, which will give an opinion on the matter within a maximum of thirty (30) days after receipt of the data.

 

5.3. The cases of pumping with evident deviations in terms of measuring will comprise immediate analysis by the PARTIES and, if they quickly identify the causes, the correct billing can be done immediately.

 

5.4. Monthly, the PARTIES will raise the total amounts billed and receive the bills from previous month in order to critically evaluate the result that is outside the monthly range defined in section 5.1.

 

5.4.1. If fully proven irregularities in the measurement of quantities invoiced, the PARTIES shall provide the correct billing within thirty (30) days after completion of the assessment of the cause.

 

-       Modes of Commercialization “Delivery in Aratu or Tramandaí” (EEA)

 

5.5. If, after the trip, the difference between the amount raised at the origin and received at the destination is outside the range of (-) 0.30% (+) 0.30% of the amount expressed at the origin, the PARTY concerned may present a global analysis of the trip. Identified the reasons causing the difference and in case of consensus between the PARTIES, the subject to adjustment quantities will be determined.

 

28

 

 

 

 

5.5.1. Regardless of the difference between the amounts expressed at the source and received at the destination if they are clearly identified “nonconformity” measurements used for billing, the interested PARTY may submit a statement identifying the reason documented cause of “noncompliance,” and in case of a consensus among PARTIES, the subject to adjustment quantities will be determined.

 

5.6. The claim shall be submitted in writing by the interested PARTY, within sixty (60) days after the unloading operation, together with any documentation that provides evidence-based claims, and the other PARTY shall pronounce itself in writing within the next 45 (forty five) days.

 

5.7. If after the end of the voyage is observed the presence of remaining on board of the BRASKEM property, it shall request reimbursement for the correctness of the amount identified is undertaken within a maximum of 30 (thirty) days and may be charged freight if the occurrence was motivated by Braskem.

 

6 – VESSELS STAY

 

-Modes of Commercialization “Delivery in Aratu of Tramandaí” (EEA)

 

6.1. The costs of demurrage at the discharge of the vessel shall be charged to the causative agent of the event.

 

6.2. To determine the demurrage costs, pumping time standards linked to the operational characteristics of the vessel used, the rules and practices of the standard form of the charter party “SHELLVOY 6” and the daily cost of stay informed monthly by PETROBRAS will serve as a base.

 

6.3. The demurrage due to inoperativeness or inefficiency of the receiving system will be the responsibility of BRASKEM

 

6.4. The demurrage due to inoperativeness or inefficiency of the operator of the discharge port shall be the responsibility of BRASKEM.

 

6.5. The demurrage due to inoperativeness or inefficiency of the ship will be responsibility of PETROBRAS.

 

6.6. PETROBRAS will have 90 (ninety) calendar days after the trip to present BRASKEM the spreadsheet that form the basis for calculating the amount to be established in the document collection.

 

6.6.1. With no agreement about the calculations presented by PETROBRAS, BRASKEM will have 5 (five) working days to appeal.

 

29

 

 

 

 

 

6.6.2. After that period established in subsection 6.6.1, the Company shall deliver charging document against BRASKEM for payment within thirty (30) days after the issuance date.

 

6.6.3. In case of default of payment, BRASKEM shall be subject to the procedures described in section 8.11 of the Agreement.

 

6.6.4. After that period of ninety (90) calendar days after the trip, and without formal presentation of the spreadsheet by PETROBRAS, referred to in item 6.6 , BRASKEM will definitely be free of any charges relating to demurrage occurred on that trip.

 

7 - VESSELS APPROVAL

 

7.1. The operation of vessels in the PETROBRAS Raw Materials Terminal in Aratu (TMP) can only occur after approval of the vessel named by PETROBRAS through the vetting procedure of Braskem.

 

7.1.1. PETROBRAS will provide the information in the “Vetting Questionnaire Braskem,” and BRASKEM should decide on the approval or rejection of a vessel within 2 (two) working days.

 

30

 

 

 

 

ANNEX III – PRICE CALCULATION

 

1. Formula to calculate the price according to item 6.1 of the Agreement:

 

Naphtha = ([*] x Ethylene  + [*] x Propylene  + [*] x Benzene  + [*] x ARA + [*]  x Marlim) x Forex

Ket                         Kpr                       Kbz

2. Example  of the price calculation for a hypothetical supply in February 2009:

 

2.1. Calculation of the Parameters:

 

Ethylene

Quarterly contract price from the Northwestern Europe ethylene market (Ethylene CP NEW), published by the ICIS, in Euros, converted to US$/t with the exchange rate published by the Central Bank of Brazil.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*].

 

[*]

 

Ethylene = [*] / [*]  = [*] US$/t

 

Propylene

 

Monthly contract price of the polymer-grade propylene in the U.S. Gulf market (Propylene GP USG), published by the ICIS, in US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

 

[*]

 

Propylene = [*] / [*] = [*] US$/t 

 

Benzene

Daily spot price of benzene in the U.S. Gulf market (Benzene SP USG), published by Platts, multiplied by a factor of 3.01308 in order to transform US$ cents/gallon to US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

 

Benzene = Benzene SP USG (average of the daily quotes from [*] to [*]) x 3.01308 = [*] US$ cents/Gal x 3.01308 = [*] US$/t

ARA

Daily average price of Physical Naphtha on the Northwestern Europe market (NWE CIF ARA), published by Platts, in US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

 

31

 

 

 

 

ARA = NWE CIF ARA average of the daily quotes from [*] to [*]) = [*] US$/t

Marlim

Daily quotation of Marlim petroleum, published by Platts, multiplied by a factor of 6.72 in order to convert US$/bbl to US$/t.  The application of the formula considers the [*] average of the quotations for the last [*] prior to supply [*]. 

Marlim = Marlim quotation (average of the daily quotes from [*] to [*]) x 6.72 Marlim = [*] US$/bbl x 6.72 = [*] US$/t

KET      Ethylene CP NWE / naphtha ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Ethylene CP NWE over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

KET (2009) = Ethylene CP NWE (average of the quotes of [*]) / NWE CIF ARA (average daily quotes of [*])
KET (2009) = [*] / [*]= [*] 

KPR      Propylene CP USG / naphtha ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Propylene CP USG over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

KPR (2009) = Propylene  CP USG (average of daily quotes [*]) / NWE CIF ARA (average of daily quotes of [*])
KPR (2009) = [*] / [*]= [*] 

KBZ      Benzene SP USG / naphtha ARA

Factor updated for each calendar [*] and calculated as the ratio of the [*] average quotations of Benzene SP USG over the last [*] and the [*] average quotations of naphtha NWE CIF ARA over the last [*].

KBZ (2009) = Benzene SP USG (average of daily quotes of [*]) / NWE CIF ARA (average of daily quotes of [*])
KPR (2009) = ([*] x [*]) / [*]  = [*] / [*]= [*] 

2.2.      Price calculation of Naphtha US$/t:

Naphtha (US$/t) = [*]  x Ethylene + [*]  x Propylene + [*]  x Benzene + [*]  x ARA + [*]  x Marlim
                                          KET                                    KpR                  KBZ

Naphtha (US$/t) = [*]  x [*] + [*]  x [*] + [*]  x [*]  + [*]  x [*] + [*]  x [*]
                                      [*]            [*]           [*]

Naphtha (US$/t) = [*]  US$/t

 

32

 

 

 

 

2.3       Checking the lower limit (floor) and top (roof) according to item 6.2 of the Agreement

Top Limit (TL) = [*]  x ARA = [*]  x [*]  = [*]  US$/t
Lower Limit (LL) = [*]  x ARA = [*]  x [*]  = [*]  US$/t

If Naphtha (US$/t) > TL; then Naphtha Petrobras (US$/t) = TL
If Naphtha (US$/t) < LL; then Naphtha Petrobras (US$/t) = LL
If LL ≤ Naphtha (US$/t) ≤ TL; then Petrobras Naphtha (US$/t) = Naphtha (US$/t)

For this example:     Naphtha (US$/t) = [*]  > LS
                                    Petrobras Naphtha (US$/t) = LS = [*]  US$/t

2.4.      Conversion of US$/t to R$/t

Exchange

Average daily prices for the sale of U.S. dollars released by the Central Bank of Brazil in the period between the first and last day of the month (N-1).

Petrobras Naphtha (R$/t) = Naphtha Petrobras (R$/t) x Exchange

Petrobras Naphtha (R$/t) = [*]  x 2.3074 = [*] =  R$/t

 

 

 

 

33loanagreement.htm

Exhibit 10.1

 

LOAN AND SECURITY AGREEMENT

 

	  

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of April 5, 2012 (the “Closing Date”) by and among MIDCAP FINANCIAL SBIC, LP, a Delaware limited partnership (“MidCap”), as administrative agent (“Agent”), the Lenders listed on Schedule 1 hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), and POLYMEDIX, INC., a Delaware corporation (“Parent”) and POLYMEDIX PHARMACEUTICALS, INC., a Delaware corporation (“PYMX” and together with Parent, individually and collectively referred to herein as “Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay Lenders.  The parties agree as follows:

 

 

1. ACCOUNTING AND OTHER TERMS

 

Accounting terms not defined in this Agreement shall be construed in accordance with GAAP.  Calculations and determinations must be made in accordance with GAAP.  Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 14.  All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.

 

 

2. LOAN AND TERMS OF PAYMENT

 

2.1 Promise to Pay.  Borrower hereby unconditionally promises to pay to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the outstanding principal amount of all Credit Extensions made by the Lenders, and accrued and unpaid interest thereon, and any other amounts due hereunder as and when due in accordance with this Agreement.

 

2.2 Term Loans.

 

(a) Availability.  Subject to the terms and conditions of this Agreement, during the Draw Period, the Lenders agree, severally and not jointly, to make one or more term loans to Borrower in an aggregate amount up to Twelve Million and 00/100 Dollars ($12,000,000.00) according to each Lender’s Term Loan Commitment as set forth on Schedule 1 hereto (such term loans are hereinafter referred to singly as a “Term Loan”, and collectively as the “Term Loans”).  After repayment, no Term Loan may be re-borrowed.  The Term Loans shall be available in two tranches.  The first tranche (“Tranche One”) shall be in an amount equal to Eight Million and 00/100 Dollars ($8,000,000.00) and shall be advanced on the Closing Date.  The second tranche (“Tranche Two”) shall be in an amount equal to Four Million and 00/100 Dollars ($4,000,000.00) and shall be available to be advanced in a single advance during the Draw Period, but only after the Tranche Two Eligibility Date.

 

(b) Interest Payments and Repayment.  Commencing on the first (1st) Payment Date following the Funding Date of Tranche One and of Tranche Two, respectively, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make monthly payments of interest to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, in arrears, and calculated as set forth in 

 

  

1

  

 

Section 2.3.  Commencing on the Amortization Date, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make consecutive monthly payments of principal to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, as calculated by Agent based upon: (i) the amount of such Lender’s Term Loans, (ii) the effective rate of interest, as determined in Section 2.3, and (iii) a straight-line amortization schedule for each Credit Extension beginning on the Amortization Date and ending on the Maturity Date.  All unpaid principal and accrued interest with respect to the Term Loans is due and payable in full on the Maturity Date.  The Term Loans may be prepaid only in accordance with Sections 2.2(c) and 2.2(d).

 

(c) Mandatory Prepayments.  If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans and all other Obligations, and all accrued and unpaid interest thereon, plus (ii) the Prepayment Fee, plus (iii) all other sums that shall have become due and payable, including Lenders’ Expenses.

 

(d) Permitted Prepayment of Loans.  Borrower shall have the option to prepay all or a portion of the Term Loans advanced by the Lenders under this Agreement; provided, however, that Borrower (i) provides written notice to Agent of its election to prepay the Term Loans at least thirty (30) days prior to such payment, and (ii) pays to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, on the date of such prepayment, an amount equal to the sum of: (A) all amount of the Term Loan and Obligations (plus accrued and unpaid interest thereon) being prepaid, plus (B) the Prepayment Fee applicable to the amount being prepaid, plus (C) all other sums that shall have become due and payable, including Lenders’ Expenses.

 

2.3 Payment of Interest on the Credit Extensions.

 

(a) Computation of Interest.  Interest on the Credit Extensions and all fees payable hereunder shall be computed on the basis of a 360-day year and the actual number of days elapsed in the period during which such interest accrues.  In computing interest on any Credit Extension, the date of the making of such Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension.

 

(b) Interest Rate Determination.  Subject to the provisions of Section 2.3(c) below, each Term Loan shall bear interest on the outstanding principal amount thereof from the date when made until paid in full at a rate per annum equal to eleven and 95/100 percent (11.95%).

 

(c) Default Rate.  Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall bear interest at a rate per annum that is five percent (5.0%) above the rate that is otherwise applicable thereto (the “Default Rate”).  Payment or acceptance of the increased interest rate provided in this Section 2.3(c) is not a permitted 

 

  

2

  

 

alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Agent or Lenders.

 

(d) Debit of Accounts.  Agent may debit any of Borrower’s Deposit Accounts, including the Designated Deposit Account, for principal and interest payments when due or any other amounts Borrower owes the Lenders under the Loan Documents when due, for payment to each Lender in accordance with its respective Pro Rata Share.  These debits shall not constitute a set-off.

 

(e) Payments.  Payments of principal and/or interest received after 12:00 Noon Eastern Time are considered received at the opening of business on the next Business Day.  When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid.  All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.  All payments required under this Agreement are to be made directly to Agent unless otherwise directed by Agent in writing.

 

(f) Maximum Lawful Rate.  In no event shall the interest charged hereunder, with respect to the notes (if any) or any other obligations of Borrower under any of the Loan Documents exceed the maximum amount permitted under the Laws of the State of Maryland.  Notwithstanding anything to the contrary herein or elsewhere, if at any time the rate of interest payable hereunder or under any note or other Loan Document (the “Stated Rate”) would exceed the highest rate of interest permitted under any applicable Law to be charged (the “Maximum Lawful Rate”), then for so long as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided, however, that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, Borrower shall, to the extent permitted by Law, continue to pay interest at the Maximum Lawful Rate until such time as the total interest received is equal to the total interest which would have been received had the Stated Rate been (but for the operation of this provision) the interest rate payable.  Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in which event this provision shall again apply.  In no event shall the total interest received by any Lender exceed the amount which it could lawfully have received, had the interest been calculated for the full term hereof at the Maximum Lawful Rate.  If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the Maximum Lawful Rate, then such excess amount shall be applied to the reduction of the principal balance of such Lender’s Term Loan or to other amounts (other than interest) payable hereunder, and if no such principal or other amounts are then outstanding, such excess or part thereof remaining shall be paid to Borrower.  In computing interest payable with reference to the Maximum Lawful Rate applicable to any Lender, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number of days in the year in which such calculation is made.

 

  

3

  

 

2.4 Fees and Expenses.  Borrower shall pay to Agent, for payment to each Lender:

 

(a) Closing Fee.

 

(i) With respect to Tranche One, a non-refundable closing fee to each Lender, in accordance with its respective Pro Rata Share, equal to the product of (i) one-half of one percent (0.50%) multiplied by (ii) Tranche One (i.e., $8,000,000). Agent, each Lender and Borrower agree the closing fee allocable to Tranche One was paid on February 15, 2012.

 

(ii) With respect to Tranche Two, a non-refundable closing fee to each Lender, in accordance with its respective Pro Rata Share, equal to the product of (i) one-half of one percent (0.50%) multiplied by (ii) Tranche Two (i.e., $4,000,000). Agent, each Lender and Borrower agree the closing fee allocable to Tranche Two shall be due and payable on the Funding Date of Tranche Two.

 

(b) Reserved.

 

(c) Prepayment Fee.  The Prepayment Fee, when due under Section 2.2(c) or 2.2(d), to each Lender, in accordance with its respective Pro Rata Share immediately prior to application of the corresponding prepayment; and

 

(d) Lenders’ Expenses.  All of Lenders’ Expenses (including reasonable attorneys’ fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Closing Date, when due (and in the absence of any other due date specified herein, such Lenders’ Expenses shall be due within five (5) Business Days of written notice).

 

2.5 Additional Costs.  If any new Law or regulation increases a Lender’s costs or reduces its income for any Term Loan, Borrower shall pay the increase in cost or reduction in income or additional expense; provided, however, that Borrower shall not be liable for any amount attributable to any period before one hundred eighty (180) days prior to the date such Lender notifies Borrower of such increased costs.  Each Lender agrees that it shall allocate any increased costs among its customers similarly affected in good faith and in a manner consistent with such Lender’s customary practice.

 

2.6 Payments and Taxes.  Any and all payments made by Borrower under this Agreement or any other Loan Document shall be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any governmental authority (including any interest, additions to tax or penalties applicable thereto) other than any taxes imposed on or measured by any Lender’s overall net income and franchise taxes imposed on it (in lieu of net income taxes), by a jurisdiction (or any political subdivision thereof) as a result of any Lender being organized or resident, conducting business (other than a business deemed to arise solely from such Lender having executed, delivered or performed its obligations or received a payment under, or enforced, or otherwise with respect to, this Agreement or any other Loan Document) or having its principal office in such jurisdiction (“Indemnified Taxes”).  If any Indemnified Taxes shall be required by Law to be withheld or deducted from or in respect of any sum payable under this Agreement or any other Loan Document to any Lender, (a) an additional amount shall be payable as may be necessary so that, after making all required withholdings or deductions 

 

  

4

  

 

(including withholdings or deductions applicable to additional sums payable under this Section) such Lender receives an amount equal to the sum it would have received had no such withholdings or deductions been made, (b) Borrower shall make such withholdings or deductions, (c) Borrower shall pay the full amount withheld or deducted to the relevant taxing authority or other authority in accordance with applicable Law, and (d) Borrower shall deliver to such Lender evidence of such payment.  Borrower’s obligation hereunder shall survive the termination of this Agreement.

 

2.7 Secured Promissory Notes.  Each Term Loan shall be evidenced by a Secured Promissory Note in the form attached as Exhibit D hereto (each a “Secured Promissory Note”), and shall be repayable as set forth herein.  Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may be) the receipt of such payment.  The outstanding amount of each Term Loan set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower hereunder or under any Secured Promissory Note to make payments of principal of or interest on any Secured Promissory Note when due.  Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.

 

2.8 Issuance of Warrants to Lenders.  Borrower has duly authorized issuance of the Warrants substantially in the form attached hereto as Exhibit E.

 

2.9 SBIC Acknowledgement.  Borrower acknowledges that Agent is a Federal licensee under the Small Business Investment Act of 1958, as amended.

 

 

3. CONDITIONS OF LOANS

 

3.1 Conditions Precedent to Initial Credit Extension.  Each Lender’s obligation to make a Term Loan is subject to the condition precedent that Agent shall consent to or shall have received, in form and substance satisfactory to Agent and Lenders, such documents, and completion of such other matters, as Agent may reasonably deem necessary or appropriate, including, without limitation:

 

(a) duly executed original signatures to this Agreement, the Perfection Certificate and the other Loan Documents to which Borrower is a party;

 

(b) duly executed original Secured Promissory Notes in favor of each Lender with a face amount equal to such Lender’s Term Loan Commitment;

 

(c) duly executed original signatures to the Control Agreements with TD Bank;

 

  

5

  

 

(d) the Operating Documents of Borrower certified by the Secretary of State of the state of organization of Borrower as of a date no earlier than thirty (30) days prior to the Closing Date;

 

(e) good standing certificates dated as of a date no earlier than thirty (30) days prior to the Closing Date to the effect that Borrower is qualified to transact business in all states in which the nature of Borrower’s business so requires;

 

(f) a duly executed original signatures to the completed Borrowing Resolutions for Borrower;

 

(g) a payoff letter from Hercules Technology Growth Capital;

 

(h) evidence that (i) the Liens securing Indebtedness owed by Borrower to Hercules Technology Growth Capital will be terminated, and (ii) the documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or control agreements, have or will, concurrently with the initial Credit Extension, be terminated;

 

(i) certified copies, dated as of a recent date, of financing statement searches, as Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released;

 

(j) an Access Agreement in respect of Borrower’s offices at 170 N. Radnor Chester Road, Suite 300, Radnor PA 19087;

 

(k) a legal opinion of Borrower’s counsel dated as of the Closing Date together with the duly executed original signatures thereto;

 

(l) evidence satisfactory to Agent that the insurance policies required by Section 6.5 hereof are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Agent, for the ratable benefit of Lenders;

 

(m) completed SBA Forms 480, 652 and 1031 and the SBIC Side Letter; and

 

(n) payment of amounts due and payable in connection with the Closing Fee described in Section 2.4(a) and the Lenders’ Expenses described in Section 2.4(d).

 

3.2 Conditions Precedent to all Credit Extensions.  The obligation of each Lender to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent:

 

(a) timely receipt by the Agent of an executed Payment/Advance Form in the form of Exhibit B attached hereto;

 

  

6

  

 

(b) the representations and warranties in Section 5 shall be true, correct and complete in all material respects on the date of the Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Default or Event of Default shall have occurred and be continuing or result from the Credit Extension.  Each Credit Extension is Borrower’s representation and warranty on that date that the representations and warranties in Section 5 remain true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; and

 

(c) there has not been any Material Adverse Change.

 

3.3 Covenant to Deliver.  Borrower agrees to deliver to Agent each item required to be delivered to Agent under this Agreement as a condition precedent to any Credit Extension.  Borrower expressly agrees that a Credit Extension made prior to the receipt by Agent of any such item shall not constitute a waiver by the Lenders of Borrower’s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in Agent’s sole discretion.

 

3.4 Procedures for Borrowing.  Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan, Borrower shall notify Agent (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 noon Eastern time fifteen (15) Business Days prior to the date the Term Loan is to be made.  Together with any such electronic or facsimile notification, Borrower shall deliver to Agent by electronic mail or facsimile a completed Payment/Advance Form executed by a Responsible Officer or his or her designee.  Upon receipt of a Payment/Advance Form, Agent shall promptly provide a copy of the same to each Lender.  Agent may rely on any telephone notice given by a person whom Agent reasonably believes is a Responsible Officer or designee.

 

 

4. CREATION OF SECURITY INTEREST

 

4.1 Grant of Security Interest.  Borrower hereby grants to Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof.  Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that may have priority by operation of applicable Law.  If Borrower shall acquire a commercial tort claim (as defined in the Code), Borrower shall promptly notify Agent in a writing signed by Borrower of the general details thereof (and further details as may be required by Agent) and grant to Agent, for the ratable 

 

  

7

  

 

benefit of the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Agent.

 

4.2 Authorization to File Financing Statements.  Borrower hereby authorizes Agent to file financing statements, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Agent’s and each Lender’s interest or rights hereunder, including a notice that any disposition of the Collateral, by either Borrower or any other Person, shall be deemed to violate the rights of Agent and the Lenders under the Code.  Agent agrees to provide a copy of any such filing to Borrower, provided, that the failure of Agent to do so shall not affect the validity or effectiveness of any such filing. Such financing statements may indicate the Collateral as “all assets of Debtor” or words of similar effect, or as being of an equal or lesser scope, or with greater detail, all in Agent’s sole discretion; provided, however, that such financing statements shall exclude from the description of “Collateral” set forth thereon Borrower’s Intellectual Property, but not the IP Proceeds, as set forth in Schedule 5.2(d).

 

 

5. REPRESENTATIONS AND WARRANTIES

 

Borrower represents and warrants as follows at all times unless expressly provided below:

 

5.1 Due Organization, Authorization: Power and Authority.

 

(a) Borrower and each of its Subsidiaries (if any) are duly existing and in good standing, as Registered Organizations in their respective jurisdictions of formation and are qualified and licensed to do business and are in good standing in any jurisdiction in which the conduct of their business or their ownership of property requires that they be qualified and licensed except where the failure to do so could not reasonably be expected to result in a Material Adverse Change.  Borrower represents and warrants that (i) Borrower’s exact legal name is that indicated on Schedule 5.1 and on the signature page hereof; (ii) Borrower is an organization of the type and is organized in the jurisdiction set forth on Schedule 5.1; (iii) Schedule 5.1 accurately sets forth Borrower’s organizational identification number or accurately states that Borrower has none; (iv) Schedule 5.1 accurately sets forth Borrower’s place of business, or, if more than one, its chief executive office as well as Borrower’s mailing address (if different than its chief executive office); and (v) Borrower (and each of its predecessors) has not, in the past five (5) years, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned by its jurisdiction.  Further, in connection with this Agreement, Borrower has delivered to Agent a completed Perfection Certificate signed by Borrower (the “Perfection Certificate”).  All other information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is accurate and complete as of the Closing Date.  If Borrower is not now a Registered Organization but later becomes one, Borrower shall promptly notify Agent of such occurrence and provide Agent with Borrower’s organizational identification number.

 

(b) The execution, delivery and performance by Borrower of the Loan Documents to which it is a party have been duly authorized, and do not (i) conflict with any of Borrower’s organizational documents; (ii) contravene, conflict with, constitute a default under or 

 

  

8

  

 

violate any material Requirement of Law; (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected; (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect); or (v) constitute an event of default under any material agreement by which Borrower or any of its Subsidiaries or their respective properties is bound.  Borrower is not in default under any agreement to which it is a party or by which it is bound in which the default could reasonably be expected to result in a Material Adverse Change.

 

5.2 Collateral.

 

(a) Collateral Accounts.  Borrower has good title to, has rights in, and has the power to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens, except Permitted Liens.  Borrower has no Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts with the banks and/or financial institutions listed on Schedule 5.2(a), for which Borrower has given Agent notice and taken such actions as are necessary to grant to Agent, for the ratable benefit of Lenders, a perfected security interest therein in accordance with Section 6.6 hereof.

 

(b) Reserved.

 

(c) Reserved.

 

(d) Intellectual Property and License Agreements.  A list of all of Borrower’s Registered Intellectual Property and all license agreements, sublicenses, or other rights of any Loan Party to use Intellectual Property (including all in-bound license agreements, but excluding over-the-counter software that is commercially available to the public) as of the date hereof and as of the date of each Compliance Certificate is set forth on Schedule 5.2(d) (as such schedule may be updated in connection with the delivery of a Compliance Certificate after the Closing Date), which indicates, for each item of property: (i) the name of Borrower owning such Registered Intellectual Property or licensee to such license agreement; (ii) Borrower’s identifier for such property (i.e., name of patent, license, etc.), (iii) whether such property is Registered Intellectual Property (or application therefor) owned by Borrower or is property to which Borrower has rights pursuant to a license agreement, and (iv) the expiration date of such Registered Intellectual Property or license agreement.  In the case of any Material Intellectual Property that is a license agreement, Schedule 5.2(d) further indicates, for each: (A) the name and address of the licensor, (B) the name and date of the agreement pursuant to which such item of Material Intellectual Property is licensed, (C) whether or not such license agreement grants an exclusive license to Borrower, (D) whether there are any purported restrictions in such license agreement as to the ability of Borrower to grant a security interest in and/or to transfer any of its rights as a licensee under such license agreement, and (E) whether a default under or termination of such license agreement could interfere with Agent’s right to sell or assign such license or any other Collateral.  Except as noted on Schedule 5.2(d), Borrower is the sole owner of its Intellectual Property, subject to Permitted IP Licenses, as identified on Schedule 5.2(d).  Each 

 

  

9

  

 

Patent is valid and enforceable and no part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, except, solely with respect to Intellectual Property that is not Material Intellectual Property, to the extent such adjudication could not reasonably be expected to result in a Material Adverse Change, and to the best of Borrower’s knowledge, no claim has been made that any part of the Intellectual Property violates the rights of any third party, except to the extent such claim could not reasonably be expected to result in a Material Adverse Change.

 

(e) Location of Collateral.  On the Closing Date, the Collateral is located at the address(es) identified on Schedule 5.2(e), and is not in the possession of any third party bailee (such as a warehouse) except as disclosed Schedule 5.2(e), and as of the Closing Date, no such third party bailee possesses components of the Collateral in excess of One Hundred Thousand Dollars ($100,000) or which constitutes Borrower’s Books.  None of the components of the Collateral (other than research and development equipment used off-site) shall be maintained at locations other than as disclosed Schedule 5.2(e) on the Closing Date or as permitted pursuant to Section 7.2.  In the event that Borrower, after the Closing Date, intends to store or otherwise deliver any portion of the Collateral (other than research and development equipment used off-site) to a bailee in excess of One Hundred Thousand Dollars ($100,000) or which constitutes Borrower’s Books, then Borrower will first receive the written consent of Agent and such bailee must execute and deliver a bailee agreement in form and substance satisfactory to Agent in its sole discretion.

 

5.3 Litigation.  Except as disclosed on Schedule 5.3 hereto, there are no actions or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than One Hundred Thousand Dollars ($100,000.00).

 

5.4 No Material Deterioration in Financial Condition; Financial Statements.  All consolidated financial statements for Borrower and any of its Subsidiaries delivered to Agent fairly present, in conformity with GAAP, in all material respects Borrower’s consolidated financial condition and Borrower’s consolidated results of operations.  There has not been any change in Borrower’s consolidated financial condition since the date of the most recent financial statements and projections submitted to Agent that would have a Material Adverse Change.

 

5.5 Solvency.  The fair salable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities.  After giving effect to the transactions described in this Agreement, (a) Borrower is not left with unreasonably small capital in relation to its business as presently conducted, and (b) Borrower is able to pay its debts (including trade debts) as they mature.

 

5.6 Regulatory Compliance.

 

(a) Borrower is not an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended.  Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its 

 

  

10

  

 

Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company”, as each term is defined and used in the Public Utility Holding Company Act of 2005.  Borrower has not violated any Laws, ordinances or rules, the violation of which could reasonably be expected to result in a Material Adverse Change.  None of Borrower’s or any of its Subsidiaries’ properties or assets has been used by Borrower or any Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in compliance with applicable Laws, except for such matters as would not reasonably be expected to result in a Material Adverse Change.  Borrower has obtained all Required Permits, or has contracted with third parties holding Required Permits, necessary for compliance with all Laws and all such Required Permits are current, except for such matters as would not reasonably be expected to result in a Material Adverse Change.  Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, except for such matters as would not reasonably be expected to result in a Material Adverse Change.

 

(b) None of the Borrower, its Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.  Neither Borrower nor, to the knowledge of Borrower, any of its Affiliates or agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.

 

5.7 Subsidiaries; Investments.  Borrower does not own any stock, partnership interest or other equity securities, except for Permitted Investments.

 

5.8 Tax Returns and Payments; Pension Contributions.  Borrower has timely filed all required income tax returns and all other material tax returns and reports, and Borrower and its Subsidiaries have timely paid all foreign, federal, state and local income taxes, and all other material assessments, deposits and contributions owed by Borrower.  Borrower may defer payment of any contested taxes, provided, however, that Borrower (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Agent in writing of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the governmental authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a “Permitted Lien”.  Borrower is unaware of any claims or adjustments proposed for any of Borrower’s prior tax years which could result in additional taxes becoming due and payable by Borrower.  Borrower has paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan 

 

  

11

  

 

which could reasonably be expected to result in any material liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency.

 

5.9 Use of Proceeds.  Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business requirements, and not for personal, family, household or agricultural purposes.  A portion of the proceeds of the initial Credit Extension shall be used on the Closing Date to repay in full the indebtedness of Borrower to Hercules Technology Growth Capital.

 

5.10 Full Disclosure.  No written representation, warranty or other statement of Borrower in any certificate or written statement given to Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).

 

5.11 Regulatory Developments.

 

(a) All Products and all material Required Permits required by applicable Laws for the manufacture sale, marketing or testing in humans of such Products are listed on Schedule 5.11 (as updated from time to time pursuant to Section 6.2(e)), and Borrower has delivered to Agent a copy of all such Required Permits as of the date hereof and to the extent requested by Agent pursuant to Section 6.2(e).

 

(b) Without limiting the generality of Section 5.6 above, (i) with respect to any Product being tested or manufactured by any Borrower or any of its Subsidiaries, such Borrower or Subsidiary has applied for and received, and such Product is the subject of, all Required Permits from Regulatory Authorities required by applicable Laws in connection with the testing or manufacture of such Product as such testing or manufacturing is currently being conducted by or on behalf of such Borrower or Subsidiary; (ii) such Borrower or Subsidiary has not received any notice from any Regulatory Authorities that (A) such Regulatory Authority is conducting an investigation or review of such Borrower’s or Subsidiary’s manufacturing facilities and processes for such Product which has disclosed any material deficiencies or violations of applicable Laws and/or such Required Permits, or (B) that any Required Permit or that any such Required Permit has been revoked or withdrawn; and (iii) no Regulatory Authority has issued any order or recommendation stating that the testing and/or manufacturing of such Product by such Borrower or Subsidiary should cease, in each case which matter could reasonably be expected to result in a Material Adverse Change.

 

(c) Without limiting the generality of Section 5.6 above, (i) with respect to any Product marketed or sold by any Borrower or any of its Subsidiaries, such Borrower or Subsidiary has applied for and received, all Required Permits from Regulatory Authorities required by applicable Laws to market and sell such Product as currently being marketed or sold 

 

  

12

  

 

by such Borrower or Subsidiary; (ii) such Borrower or Subsidiary has not received any notice from any Regulatory Authority, specifically including the FDA, that (A) such Regulatory Authority is conducting an investigation or review of any such Required Permit or (B)  that any such Required Permit has been revoked or withdrawn; and (iii) no Regulatory Authority nor has issued any order or recommendation stating that the marketing or sale of such Product should cease, or that such Product be withdrawn from the marketplace, in each case which matter could reasonably be expected to result in a Material Adverse Change.

 

(d) Without limiting the generality of Section 5.6 above, (i) there have been no adverse clinical test results, of which Borrowers has been made, or reasonably should be, aware, which have or could reasonably be expected to cause a Material Adverse Change, and (ii) there have been no Product recalls or voluntary Product withdrawals from any market.

 

 

6. AFFIRMATIVE COVENANTS

 

Borrower covenants and agrees to do all of the following:

 

6.1 Organization and Existence; Government Compliance.

 

(a) Maintain its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to result in a Material Adverse Change.  Borrower shall comply, and have each Subsidiary comply, with all Laws, ordinances and regulations to which it is subject, the noncompliance with which could reasonably be expected to result in a Material Adverse Change.

 

(b) Obtain and keep in full force and effect, all of the Governmental Approvals necessary for the performance by Borrower of its obligations under the Loan Documents to which it is a party and the grant of a security interest to Agent for the ratable benefit of the Lenders, in all of the Collateral.  Borrower shall promptly provide copies of any such obtained Governmental Approvals to Agent.

 

(c) In connection with the testing in humans, manufacture, marketing or sale of each Product by any Borrower or any of its Subsidiaries, such Borrower or Subsidiary shall comply with all Required Permits, the noncompliance with which could reasonably be expected to result in a Material Adverse Change, specifically including all Required Permits issued by the FDA, with respect to the testing in humans, manufacture, marketing or sale of such Product by such Borrower or Subsidiary, as such activities are at any such time being conducted by such Borrower or Subsidiary.

 

6.2 Financial Statements, Reports, Certificates.

 

(a) Deliver to Agent: (i) as soon as available, but no later than thirty (30) days after the last day of each month, a company prepared consolidated balance sheet and income statement of Parent, covering both Borrower’s consolidated operations for such month certified by a Responsible Officer and in a form acceptable to Agent; (ii) as soon as available, but no later than one hundred twenty (120) days after the last day of Borrower’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an 

 

  

13

  

 

unqualified opinion on the financial statements from Deloitte & Touche LLC or such other independent certified public accounting firm acceptable to Agent in its reasonable discretion; (iii) as soon as available after approval thereof by Borrower’s Board of Directors, but no later than thirty (30) days after the last day of Borrower’s fiscal year, Borrower’s financial projections for current fiscal year as approved by Borrower’s Board of Directors; (iv) unless on file with the Securities and Exchange Commission within five (5) days of delivery, copies of all statements, reports and notices made available to all of Borrower’s security holders or to any holders of Subordinated Debt; provided that, in the case of information that is filed with the Securities and Exchange Commission, Borrower shall provide Agent with written notice of such filing within five (5) days of such filing, together with a link thereto on Borrower’s or another website on the Internet; (v) a prompt report of any legal actions pending or threatened against Borrower or any of its Subsidiaries that could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of One Hundred Thousand Dollars ($100,000) or more or could result in a Material Adverse Change; and (vi) budgets, sales projections, operating plans and other financial information reasonably requested by Agent.

 

(b) Within thirty (30) days after the last day of each month, deliver to Agent with the monthly financial statements described above, a duly completed Compliance Certificate signed by a Responsible Officer.

 

(c) Keep proper books of record and account in accordance with GAAP in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities.  Borrower shall allow, at the sole cost of Borrower, Agent and Lenders to visit and inspect any of its properties, to examine and make abstracts or copies from any of Borrower’s Books, to conduct a collateral audit and analysis of its operations and the Collateral to verify the amount and age of the accounts, the identity and credit of the respective account debtors, to review the billing practices of Borrower and to discuss its respective affairs, finances and accounts with their respective officers, employees and independent public accountants as often as may reasonably be desired.  Notwithstanding the foregoing, such audits shall be conducted at Borrower’s expense no more often than once every calendar year unless a Default or Event of Default has occurred and is continuing, in which case Borrower shall be responsible for reimbursing the cost of such audits irrespective of the number that occur during a calendar year.

 

(d) Together with each Compliance Certificate delivered pursuant to Section 6.2(b), deliver to Agent an updated Schedule 5.2(d) describing any new Registered Intellectual Property that has been acquired and/or developed, indicates whether Borrower seeks to identify such new Registered Intellectual Property as Non-Material Intellectual Property and describes any other material change in Borrower’s Material Intellectual Property from that listed on Schedule 5.2(d), in each case since the date of the last Compliance Certificate.

 

(e) If, after the Closing Date, any Borrower or Subsidiary determines to test in humans or manufacture, sell, or market any new Product, such Borrower or Subsidiary (i) shall give prompt written notice to Agent of such determination (which notice shall include a brief description of such Product, plus a list of all Required Permits from Regulatory Authorities issued or outstanding as of the date of such notice), along with a copy of an updated Schedule 5.11 and (ii) shall provide Agent with a copy of all such Required Permits issued to 

 

  

14

  

 

such Borrower or Subsidiary if requested by Agent; provided, however, that if any Borrower shall at any time obtain any new or additional Required Permits from any Regulatory Authority, with respect to any Product which has previously been disclosed to Agent, such Borrower or Subsidiary shall promptly give written notice to Agent of such new or additional Required Permit and shall provide Agent with a copy thereof upon request.

 

(f)           Within ninety (90) days after the end of each fiscal year of Borrower, and at such other times as Agent may reasonably request to the extent related to SBA regulations, Borrower shall provide to Agent such forms and financial and other information with respect to any business or financial condition of Borrower or any of its Subsidiaries required by the SBA, including, but not limited to (i) forms and information with respect to Agent’s or any Lender’s reporting requirements under SBA Form 468, (ii) information regarding the full-time equivalent jobs created or retained in connection with any Lender’s investment in Borrower, the impact of the financing on Borrower’s business in terms of revenues and profits and on taxes paid by Borrower and its employees, and (iii) a list of holders of the Loans.

 

(g)           Upon request of Agent, the Borrower shall use commercially reasonable efforts to promptly (and in any event within twenty (20) days of such request) furnish to Agent all information reasonably requested, to the extent reasonably available to the Borrower in order for Agent or any Lender to comply with the requirements of 13 C.F.R. Section 107.620 or to prepare or file SBA Form 468 and any other information requested or required by the SBA.

 

6.3 Inventory; Returns.  Use commercially reasonably efforts to keep all Inventory in good and marketable condition, free from material defects.  Borrower must promptly notify Agent of all returns, recoveries, disputes and claims that involve more than Five Hundred Thousand Dollars ($500,000)].

 

6.4 Taxes; Pensions.  Timely file and require each of its Subsidiaries to timely file, all required income tax returns and all other material tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay all foreign, federal, state, and local income taxes and all other material taxes, assessments, deposits and contributions owed by Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and shall deliver to Agent, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms.

 

6.5 Insurance.  Keep its business and the Collateral insured for risks and in amounts standard for companies in Borrower’s industry and location and as Agent may reasonably request.  Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Agent.  Except as may be otherwise agreed by Agent, all property policies shall have a lender’s loss payable endorsement showing Agent as lender loss payee and waive subrogation against Agent, and all liability policies shall show, or have endorsements showing, Agent, as an additional insured.  Except as may be otherwise agreed by Agent, all policies (or the loss payable and additional insured endorsements) shall provide that the insurer shall endeavor to give Agent at least thirty (30) days notice before canceling its policy.  At Agent’s request, Borrower shall deliver certified copies of policies and evidence of all premium payments.  Proceeds payable under any policy shall, at Agent’s option, be payable to Agent on 

 

  

15

  

 

behalf of the Lenders on account of the Obligations.  If Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons and Agent, Agent may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Agent deems prudent.

 

6.6 Operating Accounts.

 

(a) Reserved.

 

(b) Provide Agent five (5) days prior written notice before establishing any Collateral Account at or with any bank or financial institution.  In addition, for each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Agent’s Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated without prior written consent of Agent.  The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s employees and identified to Agent by Borrower as such.  The information provided to Agent pursuant to this Section 6.6 shall be deemed an update to Schedule 5.2(a).

 

6.7 Protection of Intellectual Property Rights.  Borrower shall own, or be licensed to use or otherwise have the right to use, all Material Intellectual Property.  All Intellectual Property of Borrower is and shall be fully protected and/or duly and properly registered, filed or issued in the appropriate office and jurisdictions for such registrations, filings or issuances, except where the failure to do so would not reasonably be expected to result in a Material Adverse Change.  Borrower shall not become a party to, nor become bound by, any material license or other agreement with respect to which Borrower is the licensee that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or other property.  Borrower shall at all times conduct its business without knowingly infringing on any Intellectual Property rights of others.  Borrower shall do the following, to the extent it determines, in the exercise of its reasonable business judgment, that it is prudent to do so: (a) protect, defend and maintain the validity and enforceability of its Intellectual Property; (b) promptly advise Agent in writing of material infringements of its Intellectual Property; and (c) not allow any Material Intellectual Property to be abandoned, forfeited or dedicated to the public without Agent’s prior written consent.

 

6.8 Litigation Cooperation.  From the date hereof and continuing through the termination of this Agreement, make available to Agent, without expense to Agent, Borrower and its officers, employees and agents and Borrower’s Books, to the extent that Agent may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Agent with respect to any Collateral or relating to Borrower.

 

6.9 Notices of Litigation and Default.  Borrower will give prompt written notice to Agent of any litigation or governmental proceedings pending or threatened (in writing) against Borrower which would reasonably be expected to result in a Material Adverse Change.  Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in 

 

  

16

  

 

any event within three (3) Business Days) upon Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Agent of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default.

 

6.10 Creation/Acquisition of Subsidiaries.  In the event Borrower or any Subsidiary creates or, to the extent permitted hereunder, acquires any Subsidiary, Borrower and such Subsidiary shall promptly (and in any event within five (5) Business Days of such creation or acquisition) notify Agent of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably required by Agent to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents and, in each case,  grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto); and Borrower shall grant and pledge to Agent, for the ratable benefit of the Lenders, a perfected security interest in the stock, units or other evidence of ownership of each Subsidiary (the foregoing collectively, the “Joinder Requirements”); provided, that Borrower shall not be permitted to make any Investment in excess of $100,000 in such Subsidiary until such time as Borrower has satisfied the Joinder Requirements; and provided further, that Borrower shall not be required to comply with the Joinder Requirements with respect to any Foreign Subsidiary whose guarantee or grant of a Lien would result in material adverse tax consequences to Borrower under Section 956 of the “Internal Revenue Code of 1986, as amended, as determined by Agent.

 

6.11 Further Assurances.

 

(a) Promptly (but in any event within five (5) Business Days after request) execute any further instruments and take further action as Agent reasonably requests to perfect or continue Agent’s Lien in the Collateral or to effect the purposes of this Agreement.

 

(b) Deliver to Agent, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material effect on any of the Governmental Approvals material to Borrower’s business or otherwise on the operations of Borrower or any of its Subsidiaries.

 

6.12 Post-Closing Obligations.  Borrowers shall complete each of the post closing obligations and/or deliver to Agent each of the documents, instruments, agreements and information listed on Schedule 6.12 attached hereto, on or before the date set forth for each such item thereon, each of which shall be completed or provided in form and substance satisfactory to Agent and Lenders.

 

 

7. NEGATIVE COVENANTS

 

Borrower shall not do any of the following without the prior written consent of Agent and Required Lenders:

 

  

17

  

 

7.1 Dispositions.  Convey, sell, lease, transfer, assign, grant a security in or otherwise dispose of (collectively, “Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for (i) Transfers of Inventory in the Ordinary Course of Business; (ii) Permitted IP Licenses; (iii) dispositions of worn-out or obsolete Equipment at a fair market value in the Ordinary Course of Business; (iv) other Transfers of assets (other than Intellectual Property) having a fair market value of not more than $500,000 in the aggregate in any fiscal year; (v) Transfers to any Borrower, (vi) Transfers of, and transactions constituting, Permitted Investments, or (vii) Permitted Liens.  Without limiting the foregoing, Borrower agrees that it shall not grant a security interest in, nor shall it or otherwise encumber (except for encumbrances expressly permitted by clause (ii) above and clause (j) of the definition of Permitted Liens), any of its Intellectual Property without Agent’s and Required Lenders’ prior written consent.

 

7.2 Changes in Business, Management, Ownership or Business Locations.  (a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or reasonably related thereto; (b) liquidate or dissolve; (c) enter into any transaction or series of related transactions which would result in a Change in Control; (f) change its organizational structure or type; (g) without providing Agent at least five (5) Business Days prior written notice thereof, (i) change its legal name or (ii) change any organizational number (if any) assigned by its jurisdiction of organization.

 

7.3 Mergers or Acquisitions.  Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person; provided, however, that a Subsidiary of Borrower may merge or consolidate into another Subsidiary that is a Loan Party or into Borrower, so long as (a) Borrower has provided Agent with prior written notice of such transaction, (b) Borrower or such Loan Party shall be the surviving legal entity, (c) Borrower’s tangible net worth is not thereby reduced, and (d) as long as no Event of Default exists or arises as a result therefrom.

 

7.4 Indebtedness.  Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.

 

7.5 Encumbrance.  (a) Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, (b) permit any Collateral not to be subject to the first priority security interest granted herein, or (c) enter into any agreement, document, instrument or other arrangement (except with or in favor of Agent) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower or any Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower’s or any Subsidiary’s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of “Permitted Liens” herein.

 

7.6 Maintenance of Collateral Accounts.  Maintain any Collateral Account, except pursuant to the terms of Section 6.6(b) hereof.

 

  

18

  

 

7.7 Distributions; Investments.  (a) Pay any dividends (other than dividends payable solely in common stock) or make any distribution or payment on or redeem, retire or purchase any capital stock (other than repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements or similar plans), or (b) directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so.

 

7.8 Transactions with Affiliates.  Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for transactions that are in the Ordinary Course of Business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person.

 

7.9 Subordinated Debt.  (a) Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders.

 

7.10 Compliance.  Become an “investment company” or a company controlled by an “investment company”, under the Investment Company Act of 1940, as amended or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other Law or regulation, if the violation could reasonably be expected to result in a Material Adverse Change, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any unpaid material liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency.

 

7.11 Compliance with Anti-Terrorism Laws.  Agent hereby notifies Borrower that pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and its principals, which information includes the name and address of Borrower and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism Laws.  Borrower will not, nor will Borrower permit any Subsidiary or Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Borrower shall immediately notify Agent if Borrower has knowledge that Borrower or any Subsidiary or Affiliate is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.  Borrower will not, nor will Borrower permit any Subsidiary or Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, 

 

  

19

  

 

or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.

 

8. EVENTS OF DEFAULT

 

Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement:

 

8.1 Payment Default.  Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 9.1 (a) hereof).  During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period);

 

8.2 Covenant Default.

 

(a) Borrower fails or neglects to perform any obligation in Sections 6.1(c), 6.2, 6.4, 6.5, 6.6, 6.7, 6.10, 6.11, or 6.12 or violates any covenant in Section 7; or

 

(b) Borrower or any of its Subsidiaries fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in Section 8.2(a) above) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within ten (10) Business Days after the earlier of written notice from Agent or knowledge thereof by a Responsible Officer of Borrower; provided, however, that if the default cannot by its nature be cured within the ten (10) Business Day period or cannot after diligent attempts by Borrower be cured within such ten (10) Business Day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period).  Grace periods provided under this Section shall not apply, among other things, to financial covenants or any other covenants set forth in subsection (a) above;

 

8.3 Material Adverse Change.  A Material Adverse Change occurs;

 

8.4 Attachment; Levy; Restraint on Business.

 

(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or of any entity under control of Borrower (including a Subsidiary) on deposit with the Lenders or any Lender Affiliate, or (ii) a notice of lien, levy, or assessment is filed against any of Borrower’s assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed 

 

  

20

  

 

(whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; and

 

(b) (i) any material portion of Borrower’s assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower from conducting any material part of its business;

 

8.5 Insolvency.  (a) Borrower is unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b) Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within thirty (30) days (but no Credit Extensions shall be made while any of the conditions described in clause (a) exist and/or until any Insolvency Proceeding is dismissed);

 

8.6 Other Agreements.  There is a default in any agreement to which Borrower is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of One Hundred Thousand Dollars ($100,000) or that could reasonably be expected to result in a Material Adverse Change;

 

8.7 Judgments.  One or more judgments, orders, or decrees  for the payment of money in an amount, individually or in the aggregate, of at least One Hundred Thousand Dollars ($100,000) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower and shall remain unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof, provided, however, that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or decree;

 

8.8 Misrepresentations.  Borrower or any Person acting for Borrower makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Agent and/or the Lenders to induce Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made;

 

8.9 Subordinated Debt.  A default or breach occurs under any agreement between Borrower and any creditor of Borrower that signed a subordination, intercreditor, or other similar agreement with Agent or the Lenders, or any creditor that has signed such an agreement with Agent or the Lenders breaches any terms of such agreement;

 

8.10 Governmental Approvals.  Any Governmental Approval (other than a Governmental Approval issued by any Regulatory Authority, which is the subject of Section 8.14) shall have been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the Ordinary Course of Business for a full term, or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions described in clause (a) above, and in each case described in (a) and (b),  such decision or such revocation, rescission, suspension, modification or non-renewal has, or could reasonably be expected to have, a Material Adverse Change;

 

  

21

  

 

8.11 Criminal Proceeding.  The institution by any Governmental Authority of criminal proceedings against Borrower;

 

8.12 Lien Priority.  Except as permitted by Agent, any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on all of the Collateral purported to be secured thereby, subject to no prior or equal Lien;

 

8.13 Change in Control.  A Change in Control shall have occurred; or

 

8.14 Withdrawals, Recalls, Adverse Test Results and Other Matters.  Borrower ceases clinical development for both PMX-60056 and PMX-30063 as a result of either (i) an internal decision to cease all further clinical testing in humans for all indications or (ii) the institution of any action or proceeding by any Regulatory Authority to cause Borrower to cease all further clinical testing in humans for all indications.  In and of itself, (i) the failure of any nonclinical or clinical trial to demonstrate the desired safety or efficacy or (b) the denial, delay or limitation of approval of, or taking of any other regulatory action by, any Regulatory Authority shall not constitute an Event of Default under this Section 8.14.

 

9. RIGHTS AND REMEDIES

 

9.1 Rights and Remedies.

 

(a) Upon the occurrence and during the continuance of an Event of Default,  Agent may, and at the written direction of any Lender shall, without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Agent or the Lenders), or (iii) by notice to Borrower suspend or terminate the obligations, if  any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Agent and/or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to  advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Agent and/or the Lenders shall be immediately terminated without any action by Agent or the Lenders).

 

(b) Without limiting the rights of Agent and Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance of an Event of Default, Agent shall have the right, at the written direction of the Required Lenders, without notice or demand, to do any or all of the following:

 

(i) foreclose upon and/or sell or otherwise liquidate, the Collateral;

 

(ii) apply to the Obligations any (a) balances and deposits of Borrower that Agent or any Lender holds or controls, or (b) any amount held or controlled by Agent or any Lender owing to or for the credit or the account of Borrower; and/or

 

(iii) commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.

 

  

22

  

 

(c) Without limiting the rights of Agent and Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the continuance of an Event of Default Agent shall have the right, without notice or demand, to do any or all of the following:

 

(i) settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Agent considers advisable, notify any Person owing Borrower money of Agent’s security interest in such funds, and verify the amount of such Account;

 

(ii) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.  Borrower shall assemble the Collateral if Agent requests and make it available as Agent designates.  Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred.  Borrower grants Agent a license to enter and occupy any of its premises, without charge, to exercise any of Agent’s rights or remedies;

 

(iii) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral.  Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower’s labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Agent’s exercise of its rights under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements inure to Agent for the  benefit of the Lenders;

 

(iv) place a “hold” on any account maintained with Agent or the Lenders and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;

 

(v) demand and receive possession of Borrower’s Books; and

 

(vi) subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Agent under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).

 

Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Agent shall have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.  As used in the immediately preceding sentence, “Exigent Circumstance” means any event or circumstance that, in the reasonable judgment of Agent, imminently threatens the ability of Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower after reasonable demand to maintain or reinstate 

 

  

23

  

 

adequate casualty insurance coverage, or which, in the judgment of Agent, could result in a material diminution in value of the Collateral.

 

9.2 Power of Attorney.  Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to:  (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Agent or a third party as the Code permits.  Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of Agent’s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations have been satisfied in full and Agent and the Lenders are under no further obligation to make Credit Extensions hereunder.  Agent’s foregoing appointment as Borrower’s attorney in fact, and all of Agent’s rights and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Agent’s and the Lenders’ obligation to provide Credit Extensions terminates.

 

9.3 Protective Payments.  If Borrower fails to obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are Lenders’ Expenses and immediately due and payable, bearing interest at the then highest applicable rate, and secured by the Collateral.  Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter.  No such payments by Agent are deemed an agreement to make similar payments in the future or Agent’s waiver of any Event of Default.

 

9.4 Application of Payments and Proceeds.  Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Agent from or on behalf of Borrower of all or any part of the Obligations, and, as between Borrower on the one hand and Agent and Lenders on the other, Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Agent may deem advisable notwithstanding any previous application by Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of Borrower owing to Agent or any Lender under the Loan Documents.  Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct.  In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided 

 

  

24

  

 

until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category.  Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise.  Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower.  Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to the Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Agent.  If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lender’s claims.  To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis.  If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for the Agent and other Lenders for purposes of perfecting Agent’s security interest therein.  Notwithstanding anything to the contrary herein, any warrants issued to the Lenders by Borrower, the stock issuable thereunder, any equity securities purchased by Lenders, any amounts paid thereunder, any dividends, and any other rights in connection therewith shall not be subject to the terms and conditions of this Agreement.  Nothing herein shall affect any Lender’s rights under any such warrants, stock, or other equity securities to administer, manage, transfer, assign, or exercise such warrants, stock, or other equity securities for its own account.

 

9.5 Liability for Collateral.  So long as Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Agent and the Lenders, Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person.  Borrower bears all risk of loss, damage or destruction of the Collateral.

 

9.6 No Waiver; Remedies Cumulative.  Agent’s failure, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Agent thereafter to demand strict performance and compliance herewith or therewith.  No waiver hereunder shall be effective unless signed by Agent and then is only effective for the specific instance and purpose for which it is given.  Agent’s rights and remedies under this Agreement and the other Loan Documents are cumulative.  Agent has all rights and remedies provided under the Code, by Law, or in equity.  Agent’s exercise of one right or remedy is not an election, and Agent’s waiver of any Event of 

 

  

25

  

 

Default is not a continuing waiver.  Agent’s delay in exercising any remedy is not a waiver, election, or acquiescence.

 

9.7 Demand Waiver.  Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Agent on which Borrower is liable.

 

9.8 Borrower Liability.  Either Borrower may, acting singly, request Term Loans hereunder.  Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Term Loans hereunder.  Each Borrower hereunder shall be jointly and severally obligated to repay all Term Loans made hereunder and all other Obligations, regardless of which Borrower actually receives said Term Loans, as if each Borrower hereunder directly received all Term Loans.  Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, and (b) any right to require the Lenders or Agent to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy.  The Lenders or Agent may exercise or not exercise any right or remedy they have against any Borrower or any security (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower’s liability.  Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of the Lenders and Agent under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise.  Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void.  If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for the Lenders and Agent and such payment shall be promptly delivered to Agent for application to the Obligations, whether matured or unmatured.

 

 

10. NOTICES

 

All notices, consents, requests, approvals, demands, or other communication (collectively, “Communication”) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.  Any of Agent, Lender or Borrower may change its mailing or electronic mail 

 

  

26

  

 

address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10.

 

	
  

	
If to Borrower:

 

c/o PolyMedix Pharmaceuticals, Inc.

 

170 N. Radnor Chester Road, Suite 300

 

Radnor, Pennsylvania 19807

 

Attention: Edward Smith, Chief Financial Officer

 

Fax: (484) 598-2333

 

E-Mail: esmith@polymedix.com

 

	
  

	
If to Agent or Lenders:

 

MidCap Financial SBIC, LP

 

7255 Woodmont Avenue, Suite 200

 

Bethesda, Maryland  20814

 

Attention:  Portfolio Management- Life Sciences

 

Fax:  (301) 941-1450

 

E-Mail:  lviera@midcapfinancial.com

 

	
  

	
with a copy to:

 

Midcap Financial, LLC

 

7255 Woodmont Avenue, Suite 200

 

Bethesda, Maryland  20814

 

Attention:  General Counsel

 

Fax:  (301) 941-1450

 

E-Mail: rgoodridge@midcapfinancial.com

 

 

11. CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER

 

THIS AGREEMENT, EACH SECURED PROMISSORY NOTE AND EACH OTHER LOAN DOCUMENT, AND ALL MATTERS RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.  NOTWITHSTANDING THE FOREGOING, AGENT AND LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE AGENT’S AND LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY.  BORROWER EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM NON 

 

  

27

  

 

CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT.  BORROWER HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN SECTION 10 OF THIS AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER TO OCCUR OF BORROWER’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID.

 

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, AGENT AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS.  THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT.  EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.

 

Borrower, Agent and each Lender agree that each Term Loan (including those made on the Closing Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other Loan Document shall be deemed to have been performed in, the State of Maryland.

 

12. GENERAL PROVISIONS

 

12.1 Successors and Assigns.  This Agreement binds and is for the benefit of the successors and permitted assigns of each party.  Borrower may not assign this Agreement or any rights or obligations under it without Agent’s prior written consent (which may be granted or withheld in Agent’s discretion).Any Lender may at any time assign to one or more Eligible Assignees all or any portion of such Lender’s Loan, together with all related obligations of such Lender hereunder.  Borrower and Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Agent shall have received and accepted an effective assignment agreement in form and substance acceptable to Agent, executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Agent reasonably shall require.  Notwithstanding anything set forth in this Agreement to the contrary, any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided, however, that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

 

  

28

  

 

12.2 Indemnification.

 

(a) Borrower agrees to indemnify, defend and hold Agent and the Lenders and their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Agent or the Lenders  (each, an “Indemnified Person”) harmless against: (i) all obligations, demands, claims, and liabilities (collectively, “Claims”) asserted by any other party in connection with the transactions contemplated by the Loan Documents; and (ii) all losses or Lenders’ Expenses incurred, or paid by Indemnified Person from, following, or arising from transactions between Agent, and/or the Lenders and Borrower (including reasonable attorneys’ fees and expenses), except for Claims and/or losses directly caused by such Indemnified Person’s  gross negligence or willful misconduct (collectively, the “Indemnified Liabilities”).

 

(b) Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitee) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds.

 

(c) To the extent that the undertaking set forth in this Section 12.2 may be unenforceable, Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under applicable law to the payment and satisfaction of all such indemnified liabilities incurred by the Indemnitees or any of them.

 

12.3 Time of Essence.  Time is of the essence for the performance of all Obligations in this Agreement.

 

12.4 Severability of Provisions.  Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.

 

12.5 Correction of Loan Documents.  Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties.

 

12.6 Integration.  This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.

 

  

29

  

 

12.7 Counterparts.  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.

 

12.8 Survival.  All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied.  The obligation of Borrower in Section 12.2 to indemnify each Lender and Agent shall survive until the statute of limitations with respect to such claim or cause of action shall have run.

 

12.9 Confidentiality.  In handling any confidential information of Borrower, the Lenders and Agent shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (a) to the Lenders’ and Agent’s Subsidiaries or Affiliates; (b) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Agent shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to the terms of this provision); (c) as required by Law, regulation, subpoena, or other order; (d) to regulators or as otherwise required in connection with an examination or audit; (e) as Agent considers appropriate in exercising remedies under the Loan Documents; and (f) to third party service providers of the Lenders and/or Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Agent with terms no less restrictive than those contained herein.  Confidential information does not include information that either: (i) is in the public domain or in the Lenders’ and/or Agent’s possession when disclosed to the Lenders and/or Agent, or becomes part of the public domain after disclosure to the Lenders and/or Agent; or (ii) is disclosed to the Lenders and/or Agent by a third party, if the Lenders and/or Agent does not know that the third party is prohibited from disclosing the information.  Agent and/or Lenders may use confidential information for any purpose, including, without limitation, for the development of client databases, reporting purposes, and market analysis, so long as Agent and/or Lenders, as applicable, do not disclose Borrower’s identity or the identity of any Person associated with Borrower unless otherwise expressly permitted by this Agreement.  The provisions of the immediately preceding sentence shall survive the termination of this Agreement.  The agreements provided under this Section 12.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 12.9.

 

12.10 Right of Set Off.  Borrower hereby grants to Agent and to each Lender, a lien, security interest and right of set off as security for all Obligations to Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Agent or the Lenders or any entity under the control of Agent or the Lenders (including a Agent affiliate) or in transit to any of them.  At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.  ANY AND ALL RIGHTS TO REQUIRE AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE 

 

  

30

  

 

OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.

 

12.11 [Reserved].

 

12.12 Amendments.

 

(a) No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Agent and the Required Lenders, provided, however, that

 

(i) no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender’s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender’s written consent;

 

(ii) no such amendment, waiver or modification that would affect the rights and duties of Agent shall be effective without Agent’s written consent or signature;

 

(iii) no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for Lenders to take any action hereunder; (D) release all or substantially all or any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive or otherwise modify this Section 12.12 or the definitions of the terms used in this Section 12.12 insofar as the definitions affect the substance of this Section 12.12; (F) consent to the assignment, delegation or other transfer by any Borrower or any Guarantor of any of its rights and obligations under any Loan Document or release Borrower or any Guarantor of its payment obligations under any Loan  Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10.  It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence;

 

  

31

  

 

(iv) the provisions of the foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the Agent and Lenders pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders.

 

(b) Other than as expressly provided for in Section 12.12(a)(i) through (iii) above, Agent may, if requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative of the Borrower.

 

12.13 Publicity.  Borrower will not directly or indirectly publish, disclose or otherwise use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of Agent or any Lender or any of their Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except (i) such filings and disclosures as Borrower shall determine to be necessary or appropriate under federal securities law, (ii) as required by applicable Law, subpoena or judicial or similar order, in which case Borrower shall endeavor to give Agent prior written notice of such disclosure or (ii) without first providing Agent and such Lender(s) with an opportunity to review and confer with Borrower regarding, and approve, the contents of any such advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same advertisement or information shall not require Agent’s or such Lender(s)’ approval.  Each Lender and Borrower hereby authorizes each Lender to publish the name of such Lender and Borrower, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”, comparable advertisement or press release which such Lender elects to submit for publication.  In addition, each Lender and Borrower agrees that each Lender may provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements after the Closing Date.  With respect to any of the foregoing, such authorization shall be subject to such Lender providing Borrower and the other Lenders with an opportunity to review and confer with such Lender regarding, and approve, the contents of any such tombstone, advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same tombstone, advertisement or information shall not require Borrower’s approval.

 

12.14 No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

 

13. AGENT

 

13.1 Appointment and Authorization of Agent.  Each Lender hereby irrevocably appoints, designates and authorizes Agent to take such action on its behalf under the provisions of this Agreement and each other Loan Document and to exercise such powers and perform such

 

  

32

  

 

duties as are expressly delegated to it by the terms of this Agreement or any other Loan Document, together with such powers as are reasonably incidental thereto.  Notwithstanding any provision to the contrary contained elsewhere herein or in any other Loan Document, Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against Agent.  Without limiting the generality of the foregoing sentence, the use of the term “agent” herein and in the other Loan Documents with reference to Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law.  Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties.

 

13.2 Delegation of Duties.  Agent may execute any of its duties under this Agreement or any other Loan Document by or through its, or its Affiliates’, agents, employees or attorneys-in-fact and shall be entitled to obtain and rely upon the advice of counsel and other consultants or experts concerning all matters pertaining to such duties.  Agent shall not be responsible for the negligence or misconduct of any agent or attorney-in-fact that it selects in the absence of gross negligence or willful misconduct.

 

13.3 Liability of Agent.  Except as otherwise provided herein, no Agent-Related Person shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby (except for its own gross negligence or willful misconduct in connection with its duties expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement, representation or warranty made by Borrower or any officer thereof, contained herein or in any other Loan Document, or in any certificate, report, statement or other document referred to or provided for in, or received by Agent under or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document, or for any failure of Borrower or any other party to any Loan Document to perform its obligations hereunder or thereunder.  No Agent-Related Person shall be under any obligation to any Lender or participant to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of Borrower or any Affiliate thereof.

 

13.4 Reliance by Agent.  Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, communication, signature, resolution, representation, notice, consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message, electronic mail message, statement or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to Borrower), independent accountants and other experts selected by Agent.  Agent shall be fully justified in failing or refusing to take any action under any Loan Document unless it shall first receive such advice or concurrence of all Lenders as it deems appropriate and, if it so requests, it shall first be indemnified to its satisfaction by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action.  Agent shall in all cases be fully protected in acting, or in 

 

  

33

  

 

refraining from acting, under this Agreement or any other Loan Document in accordance with a request or consent of all Lenders and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders.

 

13.5 Notice of Default.  Agent shall not be deemed to have knowledge or notice of the occurrence of any Default and/or Event of Default, unless Agent shall have received written notice from a Lender or Borrower, describing such default or Event of Default.  Agent will notify the Lenders of its receipt of any such notice.  Agent shall take such action with respect to an Event of Default as may be directed in writing by the Required Lenders in accordance with Section 9(a); provided, however, that while an Event of Default has occurred and is continuing, Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default as Agent shall deem advisable or in the best interest of the Lenders, including without limitation,  satisfaction of other security interests, liens or encumbrances on the Collateral not permitted under the Loan Documents, payment of taxes on behalf of Borrower, payments to landlords, warehouseman, bailees and other Persons in possession of the Collateral and other actions to protect and safeguard the Collateral, and actions with respect to insurance claims for casualty events affecting Borrower and/or the Collateral.

 

13.6 Credit Decision; Disclosure of Information by Agent.  Each Lender acknowledges that no Agent-Related Person has made any representation or warranty to it, and that no act by Agent hereafter taken, including any consent to and acceptance of any assignment or review of the affairs of Borrower or any Affiliate thereof, shall be deemed to constitute any representation or warranty by any Agent-Related Person to any Lender as to any matter, including whether Agent-Related Persons have disclosed material information in their possession.  Each Lender represents to Agent that it has, independently and without reliance upon any Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own appraisal of, and investigation into, the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower and its respective Subsidiaries, and all applicable bank or other regulatory Laws relating to the transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to Borrower hereunder.  Each Lender also represents that it will, independently and without reliance upon any Agent-Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower.  Except for notices, reports and other documents expressly required to be furnished to the Lenders by Agent herein, Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of Borrower or any of its Affiliates which may come into the possession of any Agent-Related Person.

 

13.7 Indemnification of Agent.  Whether or not the transactions contemplated hereby are consummated, each  Lender shall, severally and pro rata based on its respective Pro Rata Share, indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on behalf of Borrower and without limiting the obligation of Borrower to do so), and hold harmless each Agent-Related Person from and against any and all Indemnified Liabilities (which 

 

  

34

  

 

shall not include legal expenses of Agent incurred in connection with the closing of the transactions contemplated by this Agreement) incurred by it; provided, however, that no Lender shall be liable for the payment to any Agent-Related Person of any portion of such Indemnified Liabilities to the extent determined in a judgment by a court of competent jurisdiction to have resulted from such Agent-Related Person’s own gross negligence or willful misconduct; provided, however, that no action taken in accordance with the directions of the Required Lenders shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section 13.7.  Without limitation of the foregoing, each Lender shall, severally and pro rata based on its respective Pro Rata Share, reimburse Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including Lenders’ Expenses incurred after the closing of the transactions contemplated by this Agreement) incurred by Agent (in its capacity as Agent, and not as a Lender) in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, any other Loan Document, or any document contemplated by or referred to herein, to the extent that Agent is not reimbursed for such expenses by or on behalf of Borrower.  The undertaking in this Section 13.7 shall survive the payment in full of the Obligations, the termination of this Agreement and the resignation of Agent.

 

13.8 Agent in its Individual Capacity.  With respect to its Credit Extensions, MidCap shall have the same rights and powers under this Agreement as any other Lender and may exercise such rights and powers as though it were not Agent, and the terms “Lender” and “Lenders” include MidCap in its individual capacity.

 

13.9 Successor Agent.

 

(a) Agent may at any time assign its rights, powers, privileges and duties hereunder to (i) another Lender, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned (or will assign, in conjunction with such assignment of agency rights hereunder) 50% or more of its Loan, in each case without the consent of the Lenders or Borrowers.  Following any such assignment, Agent shall give notice to the Lenders and Borrowers.  An assignment by Agent pursuant to this subsection (a) shall not be deemed a resignation by Agent for purposes of subsection (b) below.

 

(b) Without limiting the rights of Agent to designate an assignee pursuant to subsection (a) above, Agent may at any time give notice of its resignation to the Lenders and Borrowers.  Upon receipt of any such notice of resignation, Required Lenders shall have the right to appoint a successor Agent.  If no such successor shall have been so appointed by Required Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation, then the retiring Agent may, on behalf of the Lenders, appoint a successor Agent; provided, however, that if Agent shall notify Borrowers and the Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice from Agent that no Person has accepted such appointment and, from and following delivery of such notice, (i) the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents, and (ii) all payments, communications and determinations provided to be made by, 

 

  

35

  

 

to or through Agent shall instead be made by or to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this subsection (b).

 

(c) Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s appointment as Agent pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties and obligations hereunder and under the other Loan Documents (if not already discharged therefrom as provided above in this subsection (c)).  The fees payable by Borrowers to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between Borrower and such successor.  After the retiring Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Section 13 shall continue in effect for the benefit of such retiring Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent.

 

13.10 Agent May File Proofs of Claim.  In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to Borrower, Agent (irrespective of whether the principal of any Loan, shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether Agent shall have made any demand on Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:

 

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Credit Extensions and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and Agent and their respective agents and counsel and all other amounts due the Lenders and Agent allowed in such judicial proceeding); and

 

(b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

 

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to Agent and, in the event that Agent shall consent to the making of such payments directly to the Lenders, to pay to Agent any amount due for the reasonable compensation, expenses, disbursements and advances of Agent and its agents and counsel, and any other amounts due Agent under Section 2.4(d).  To the extent that Agent fails timely to do so, each Lender may file a claim relating to such Lender’s claim.

 

13.11 Collateral and Guaranty Matters.  The Lenders irrevocably authorize Agent, at its option and in its discretion, to release any Guarantor and any Lien on any Collateral granted to or held by Agent under any Loan Document (a) upon the date that all Obligations due hereunder have been fully and indefeasibly paid in full and no Term Loan Commitments or other obligations of any Lender to provide funds to Borrower under this Agreement remain outstanding, (b) that is transferred or to be transferred as part of or in connection with any 

 

  

36

  

 

Transfer permitted hereunder or under any other Loan Document, or (c) as approved in accordance with Section 12.11.  Upon request by Agent at any time, all Lenders will confirm in writing Agent’s authority to release its interest in particular types or items of Property, pursuant to this Section 13.11.

 

13.12 Cooperation of Borrower.  If necessary, Borrower agrees to (a) execute any documents (including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section 12.1, (b) make Borrower’s management available to meet with Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions and (c) assist Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request.  Subject to the provisions of Section 12.9 Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this Agreement.

 

 

14. DEFINITIONS

 

As used in this Agreement, the following terms have the following meanings:

 

“Access Agreement” means a landlord consent, bailee letter or warehouseman’s letter, in form and substance reasonably satisfaction to Agent, in favor of Agent executed by such landlord, bailee or warehouseman, as applicable, for any third party location.

 

“Account” means any “account”, as defined in the Code, with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower.

 

“Account Debtor” means any “account debtor”, as defined in the Code, with such additions to such term as may hereafter be made.

 

“Affiliate” means, with respect to any Person, a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person’s managers and members.

 

“Agent” means, MidCap, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.

 

“Agent-Related Person” means the Agent, together with its Affiliates, and the officers, directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided, however, that no Agent-Related Person shall be an Affiliate of Borrower.

 

“Agreement” has the meaning given it in the preamble of this Agreement.

 

  

37

  

 

“Amortization Date” means February 1, 2013.

 

“Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC.

 

“Approved Fund” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the Ordinary Course of Business, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.

 

“Blocked Person” means: (a) any Person listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list.

 

“Borrower” has the meaning given it in the preamble of this Agreement.

 

“Borrower’s Books” means all of Borrower’s books and records, including ledgers, federal and state tax returns, records regarding Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.

 

“Borrowing Resolutions” means, with respect to any Person, those resolutions adopted by such Person’s Board of Directors and delivered by such Person to Agent approving the Loan Documents to which such Person is a party and the transactions contemplated thereby, together with a certificate executed by its secretary on behalf of such Person certifying that (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Loan Documents to which it is a party, (b) that attached as an Exhibit to such certificate is a true, correct, and complete copy of the resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Loan Documents to which it is a party, (c) the name(s) of the Person(s) authorized to execute the Loan Documents on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Agent and the Lenders may conclusively rely on such certificate unless and until such Person shall have delivered to Agent a further certificate canceling or amending such prior certificate.

 

  

38

  

 

“Business Day” means any day that is not a Saturday, Sunday or a day on which Agent is closed.

 

“Capital Lease Obligations” means the balance sheet amount of any obligations in respect of leases required to be capitalized in accordance with GAAP as in effect on the date hereof.

 

“Cash Equivalents” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than two (2) years from the date of acquisition, (b) commercial paper maturing no more than one (2) years after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc., (c) certificates of deposit issued maturing no more than two (2) years after issue, and (d) money market funds at least ninety-five percent (95%) of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (b) of this definition.  For the avoidance of doubt, the direct purchase by Borrower, co-borrower, or any subsidiary of Borrower of any Auction Rate Securities, or purchasing participations in, or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by Borrower, co-borrower, or any subsidiary of Borrower shall be conclusively determined by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this agreement governing Permitted Investments.  Notwithstanding the foregoing, Cash Equivalents does not include, and each Borrower and Subsidiary is prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an auction rate security.

 

“Change in Control” means any event, transaction, or occurrence as a result of which (a) any “person” (as such term is defined in Sections 3(a)(9) and 13(d)(3) of the Exchange Act), other than a trustee or other fiduciary holding securities under an employee benefit plan of Borrower, is or becomes a beneficial owner (within the meaning Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities of Borrower, representing 35% or more of the combined voting power of Borrower’s then outstanding securities; (b) during any period of twelve consecutive calendar months, individuals who at the beginning of such period constituted the Board of Directors of Borrower (together with any new directors whose election by the Board of Directors of Borrower was approved by a vote of not less than two-thirds of the directors then still in office who either were directors at the beginning of such period  or whose election or nomination for election was previously so approved) cease for any reason other than death or disability to constitute a majority of the directors then in office; (c) Borrower ceases to own and control, directly or indirectly, all of the economic and voting rights associated with the outstanding securities of each of its Subsidiaries; or (d) the occurrence of any “change of control” or any term of similar effect under any Subordinated Debt document.

 

“Claims” has the meaning given it in Section 12.2.

 

“Closing Date” has the meaning given it in the preamble of this Agreement.

 

  

39

  

 

“Code” means the Uniform Commercial Code in effect on the date hereof, as the same may, from time to time, be enacted and in effect in the State of Maryland; provided, however, that to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; and provided, further, that in the event that, by reason of mandatory provisions of Law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of Maryland, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.

 

“Collateral” means all property, now existing or hereafter acquired described in Exhibit A hereto or in any other Loan Document that contains a grant of a security interest by a Borrower.

 

“Collateral Account” means any Deposit Account, Securities Account or Commodity Account.

 

“Commitment Percentage” means, as to any Lender, the percentage set forth opposite such Lender’s name on Schedule 1, as amended from time to time.

 

“Commodity Account” means any “commodity account”, as defined in the Code, with such additions to such term as may hereafter be made.

 

“Communication” has the meaning given it in Section 10.

 

“Compliance Certificate” means a certificate, duly executed by an authorized officer of Borrower, appropriately completed and substantially in the form of Exhibit C.

 

“Contingent Obligation” means, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not include endorsements in the Ordinary Course of Business.  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.

 

“Control Agreement” means any control agreement entered into among the depository institution at which Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Agent pursuant to which Agent obtains control (within the meaning of

 

  

40

  

 

the Code) for the benefit of the Lenders over such Deposit Account, Securities Account or Commodity Account.

 

“Credit Extension” means any Term Loan or any other extension of credit by Agent or the Lenders for Borrower’s benefit.

 

“DEA” means the Drug Enforcement Administration of the United States of America, and any successor agency thereof.

 

“Default” means any event which with notice or passage of time or both, would constitute an Event of Default.

 

“Default Rate” has the meaning given it in Section 2.3(c).

 

“Deposit Account” means any “deposit account” as defined in the Code with such additions to such term as may hereafter be made.

 

“Designated Deposit Account” means Borrower’s deposit account, account number 424-4667890, maintained with TD Bank and over which Agent has been granted control for the ratable benefit of all Lenders.

 

“Dollars,” “dollars” and “$” each means lawful money of the United States.

 

“Draw Period” means the period of time commencing upon the Closing Date and continuing through the earliest to occur of (a) the Draw Period Termination Date and (b) an Event of Default.

 

“Draw Period Termination Date” means September 30, 2012.

 

“Drug Application” means a new drug application, an abbreviated drug application, or a product license application for any Product, as appropriate, as those terms are defined in the FDCA.

 

“Eligible Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent; provided, however, that notwithstanding the foregoing, “Eligible Assignee” shall not include Borrower, any Guarantor or any of Borrower’s or any Guarantor’s Affiliates or Subsidiaries.  Notwithstanding the foregoing, in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party becoming an assignee incident to such forced divestiture.

 

“Equipment” means all “equipment”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, and all regulations promulgated thereunder.

 

  

41

  

 

“Event of Default” has the meaning given it in Section 8.

 

“Exclusive License” means, in respect of any Intellectual Property, a license that grants the licensee the exclusive rights to exploit such Intellectual Property for all uses and indications.

 

“FDA” means the Food and Drug Administration of the United States of America, or any successor entity thereto.

 

“FDCA” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder.

 

“Foreign Subsidiary” means any Subsidiary that is not organized, incorporated or otherwise formed under the laws of the United States or any State thereof.

 

“Funding Date” means any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.

 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination.

 

“General Intangibles” means all “general intangibles”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable Law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including, without limitation, key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.

 

“Governmental Approval” means any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.

 

“Governmental Authority” means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.

 

“Guarantor” means any present or future guarantor of the Obligations.

 

  

42

  

 

“Indebtedness” means (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) Capital Lease Obligations, and (d) Contingent Obligations.

 

“Indemnified Liabilities” has the meaning given it in Section 12.2.

 

“Indemnified Person” has the meaning given it in Section 12.2.

 

“Insolvency Proceeding” means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency Law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

 

“Intellectual Property” means all intellectual property and similar rights, including without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

 

“Interest Expense” means for any fiscal period with respect to Borrower and its Subsidiaries on a consolidated basis, interest expense (whether cash or non-cash) determined in accordance with GAAP for the relevant period ending on such date, including, in any event, interest expense with respect to any Credit Extension and other Indebtedness of Borrower and its Subsidiaries, including, without limitation or duplication, all commissions, discounts, or related amortization and other fees and charges with respect to letters of credit and bankers’ acceptance financing and the net costs associated with interest rate swap, cap, and similar arrangements, and the interest portion of any deferred payment obligation (including leases of all types).

 

“Inventory” means all “inventory”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of Borrower’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.

 

“Investment” means any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance or capital contribution to any Person.

 

“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial decisions, regulations, guidances, guidelines, ordinances, rules, judgments, orders, 

 

  

43

  

 

decrees, codes, plans, injunctions, permits, concessions, grants, franchises, governmental agreements and governmental restrictions, whether now or hereafter in effect, which are applicable to any Borrower in any particular circumstance.

 

“Lender” means any one of the Lenders.

 

“Lenders” means the Persons identified on Schedule 1 hereto, and each assignee that becomes a party to this Agreement pursuant to Section 12.1.

 

“Lenders’ Expenses” means all reasonable, customary and documented audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and expenses) of Agent and Lenders for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Agent or the Lenders in connection with the Loan Documents.

 

“Lien” means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind, whether voluntarily incurred or arising by operation of Law or otherwise against any property.

 

“Loan Documents” means, collectively, this Agreement, the Warrant, the Perfection Certificate, the IP Agreement, any note, or notes or guaranties executed by Borrower or any Guarantor in connection with the indebtedness governed by this Agreement, and any other present or future agreement between Borrower and/or for the benefit of the Lenders and Agent in connection with this Agreement, all as amended, restated, or otherwise modified.

 

“Loan Party” means Borrower and each Guarantor.

 

“Material Adverse Change” means a material adverse change in: (i) the business, operations, properties, assets, or condition (financial or otherwise) of Borrower and its Subsidiaries taken as a whole or (ii) the ability of Borrower to perform the secured obligations in accordance with the terms of the loan documents, or the ability of Agent to enforce any of its rights or remedies with respect to the secured obligations; or (iii) the value of the Collateral and Intellectual Property in the aggregate; or (iv) material impairment in the perfection or priority of Agent’s liens on the Collateral.

 

“Material Intellectual Property” means all of Borrower’s Intellectual Property and license or sublicense agreements or other agreements with respect to rights in Intellectual Property that are material to the condition (financial or other), business or operations of Borrower, as determined by Agent in its good faith credit judgment; it being agreed that, unless Agent otherwise advises Borrower in writing, and with the exception of Non-Material Intellectual Property, all of Borrower’s Intellectual Property and other assets described in this definition, whether owned on the Closing Date or acquired or developed thereafter, shall be “Material Intellectual Property.”

 

“Maturity Date” means July 1, 2015 for each Term Loan.

 

  

44

  

 

“Non-Material Intellectual Property” means (a) the Intellectual Property designated as “Non-Material Intellectual Property” on Schedule 5.2(d) as of the Closing Date and (b) the Intellectual Property acquired or developed following the Closing Date that is designated as such on any Compliance Certificate delivered after the Closing Date (but only to the extent Agent has not advised Borrower in writing that it does not agree with such designation); provided that, for the avoidance of doubt, no Intellectual Property that is Material Intellectual Property on the Closing Date shall be designated as Non-Material Intellectual Property after the Closing Date unless expressly consented to by Agent in its good faith credit judgment.

 

“Obligations” means all of Borrower’s obligations to pay when due any debts, principal, interest, Lenders’ Expenses, the Prepayment Fee, and other amounts Borrower owes the Lenders now or later, under this Agreement or the other Loan Documents, including, without limitation, interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Agent, and the performance of Borrower’s duties under the Loan Documents.

 

“OFAC” means the U.S. Department of Treasury Office of Foreign Assets Control.

 

“OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

 

“Operating Documents” means, for any Person, such Person’s formation documents, as certified with the Secretary of State of such Person’s state of formation on a date that is no earlier than 30 days prior to the Closing Date, and (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.

 

“Ordinary Course of Business” means, in respect of any transaction involving any Loan Party, the ordinary course of business of such Loan Party.

 

“Payment/Advance Form” means that certain form attached hereto as Exhibit B.

 

“Payment Date” means the first calendar day of each calendar month, or if such day is not a Business Day, the next following Business Day.

 

“Perfection Certificate” has the meaning given it in Section 5.1.

 

“Permit” means any license, certificate, accreditation, product clearance or approval, provider number or provider authorization, marketing authorization, other authorization, registration, permit, consent or approval that is issued by a Governmental Authority and required in connection with the conduct of Borrower’s or any Subsidiary’s business or to comply with any applicable Laws, including, without limitation, drug listings and drug establishment registrations 

 

  

45

  

 

under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product).

 

“Permitted IP Licenses” means any of the following licenses for the use of Intellectual Property in the Ordinary Course of Business, but, in each case, only to the extent such license could not result in a legal transfer of title of the licensed Intellectual Property:

 

(a)           licenses by any Borrower or any of its Subsidiaries of Intellectual Property that are not Exclusive Licenses;

 

(b)           Exclusive Licenses by any Borrower or any of its Subsidiaries of Intellectual Property for non-therapeutic uses;

 

(c)           Exclusive Licenses by any Borrower or any of its Subsidiaries of Intellectual Property covering any compound or substance that has not been tested in humans as of the date of the applicable Exclusive License;

 

(d)           Exclusive Licenses by any Borrower or any of its Subsidiaries of Intellectual Property for use outside of North America;

 

(e)           Exclusive Licenses by any Borrower or any of its Subsidiaries of Intellectual Property covering the Product PMX-30063 in North America, provided, that (i) Borrower receives up front proceeds in an amount at least equal to the lesser of (x) $20,000,000 or (y) two times the principal balance of the Loan outstanding as of the date of the applicable Exclusive Licenses, and (ii) following receipt of the aforesaid upfront proceeds the Borrower has cash on hand in an amount at least equal to the Projected Cash Burn for the twelve month period commencing with the month in which such Borrower entered into such Exclusive License;

 

(f)           Exclusive Licenses by any Borrower or any of its Subsidiaries of Intellectual Property covering the Product PMX-60056 in North America; provided that, following receipt of any upfront proceeds payable in connection with the applicable Exclusive Licenses, the Borrower has cash on hand in an amount at least equal to the Projected Cash Burn for the twelve month period commencing with the month in which such Borrower entered into such Exclusive License; and

 

(g)           any other license of Intellectual Property for use within North America that is approved in writing by Agent prior to entry into such license.

 

“Permitted Indebtedness” means:

 

(a) Borrower’s Indebtedness to the Lenders and Agent under this Agreement and the other Loan Documents;

 

(b) Indebtedness existing on the Closing Date and described on Schedule 7.4;

 

(c) Indebtedness of up to $1,000,000 outstanding at any time secured by a Lien described in clause (c) of the defined term “Permitted Liens”, provided such Indebtedness 

 

  

46

  

 

does not exceed the lesser of the cost or fair market value of Equipment financed with such Indebtedness;

 

(d) Unsecured Indebtedness to trade creditors incurred in the Ordinary Course of Business;

 

(e) Indebtedness incurred in the Ordinary Course of Business with respect to corporate credit cards so long as (i) such Indebtedness is secured only by cash or Cash Equivalents and (ii) the aggregate amount of all such Indebtedness does not exceed $500,000 at any time outstanding;

 

(f) Indebtedness that also constitutes a Permitted Investment;

 

(g) Subordinated Debt;

 

(h) Reimbursement obligations in connection with letters of credit that are (i) outstanding on the Closing Date; (ii) secured by cash or cash equivalents and (iii) issued on behalf of the Borrower or a Subsidiary in an amount not to exceed $1,000,000 at any time outstanding;

 

(i) Other unsecured Indebtedness in an amount not to exceed $100,000 at any time outstanding; and

 

(j) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (h) above, provided, however, that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be.

 

“Permitted Investments” means:

 

(a) Investments existing on the Closing Date and described on Schedule 7.7;

 

(b) Investments consisting of Cash Equivalents;

 

(c) Investments in Subsidiaries solely to the extent permitted pursuant to Section 6.10;

 

(d) Investments consisting of cash advances to employees for business-related expenses in the Ordinary Course of Business in an aggregate amount not to exceed $50,000 in any fiscal year; and

 

(e) additional Investments that do not exceed $500,000 in the aggregate amount outstanding at any time.

 

“Permitted Liens” means:

 

(a) Liens existing on the Closing Date and shown on the Perfection Certificate or arising under this Agreement and the other Loan Documents;

 

  

47

  

 

(b) Liens for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and for which Borrower maintains adequate reserves on its Books in accordance with GAAP, provided, however, that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended , and the Treasury Regulations adopted thereunder;

 

(c) purchase money Liens (i) on Equipment acquired or held by Borrower incurred for financing the acquisition of the Equipment securing no more than One Million Dollars ($1,000,000) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the Equipment;

 

(d) statutory Liens securing claims or demands of materialmen, mechanics, carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided, however, that they have no priority over any of Agent’s Lien and the aggregate amount due and unpaid to such Persons does not any time exceed Twenty Five Thousand Dollars ($25,000);

 

(e) leases or subleases of real property granted in the Ordinary Course of Business, and leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or Intellectual Property) granted in the Ordinary Course of Business, if the leases, subleases, licenses and sublicenses do not prohibit granting Agent a security interest;

 

(f) banker’s liens, rights of setoff and Liens in favor of financial institutions incurred made in the Ordinary Course of Business arising in connection with Borrower’s deposit accounts or securities accounts held at such institutions to secure payment of fees and similar costs and expenses subject to Borrower’s compliance with Section 6.6(b) hereof;

 

(g) Liens to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the Ordinary Course of Business (other than Liens imposed by ERISA), or to secure appeal bonds;

 

(h) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.5 or 8.7;

 

(i) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and similar charges or encumbrances affecting real property not constituting a Material Adverse Change;

 

(j) Permitted IP Licenses;

 

(k) Liens in favor of customs or revenue authorities arising as a matter of law to secure payment of customs duties that are promptly paid;

 

(l) Liens on Cash Equivalents securing obligations permitted under clauses (e) and (h) of the definition of Permitted Indebtedness; and

 

  

48

  

 

(m) Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) and (c) above, but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness may not increase.

 

“Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.

 

“Prepayment Fee” means with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to:

 

(a) for a prepayment made on or after the Closing Date through and including the date which is twelve (12)  months after the Closing Date, three percent (3.0%) multiplied by the principal amount of the Term Loan that is prepaid;

 

(b) for a prepayment made after the date which is twelve (12) months after the Closing Date through and including the date which is twenty-four (24)  months after the Closing Date, two percent (2.0%) multiplied by the principal amount of the Term Loan that is prepaid; and

 

(c) for a prepayment made after the date which is twenty-four (24) months after the Closing Date through and including the date which is thirty-six (36) months after the Closing Date, one percent (1.0%) multiplied by the principal amount of the Term Loan that is prepaid.

 

Provided, however, that in the event Borrower has (i) provided a written request for approval of an Exclusive License of Intellectual Property pursuant to clause (g) of the definition of Permitted IP Licenses, (ii) the Board of Directors of the Borrower proposing to grant such Exclusive License has approved such proposed Exclusive License, as certified by an officer of such Borrower, and (iii) Agent has not granted such approval within thirty (30) days after receipt of such request, then if Borrower prepays the Loans in full on or prior to the date of entry into the license that was the subject of such approval request (on the same terms as those presented to Agent for approval) but in any event within sixty (60) days after the earlier of (a) the date on which Agent advises Borrower that it does not approve of such license or (b) the expiration of the thirty (30) day approval period referenced in (iii) above, the Prepayment Fee shall equal $0.

 

“Pro Rata Share” means, as determined by Agent, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the amount of Term Loans held by such Lender by the aggregate amount of all outstanding Term Loans.

 

“Product” means (i) any compound or substance that is the subject of a Permit for testing in humans held by any Borrower or any Subsidiary or (ii) any product manufactured, sold, or marketed by any Borrower or any of its Subsidiaries, including without limitation, those products set forth on Schedule 5.11 (as updated from time to time in accordance with Section 6.2(e)

 

  

49

  

 

above); provided, however, that if Borrower shall fail to comply with the obligations under Section 6.2(e) to give notice to Agent and update Schedule 5.11 prior to testing any new compound or substance in humans, or manufacturing, selling, developing (i.e., testing in humans) or marketing any new product, any such compound, substance or product shall nonetheless be deemed a “Product” included in this definition; and provided, further, that any products manufactured by any Borrower or any of its Subsidiaries for unaffiliated third parties shall not be deemed “Products” hereunder.

 

“Projected Cash Burn” means, in connection with any Exclusive License pursuant to clause (e) or  (f) of the definition of Permitted IP License, the forecast net cash outflows of the Borrower for the twelve (12) month period commencing with the month in which such Exclusive License is entered into based on projections prepared in good faith by management of Borrower based on assumptions believed to be reasonable and provided to Agent not less than five (5) Business Days prior to the consummation of such Permitted IP License.

 

“Registered Intellectual Property” means registered copyrights, registered trademarks, patents and applications for any of the foregoing.

 

“Registered Organization” means any “registered organization” as defined in the Code, with such additions to such term as may hereafter be made.

 

“Regulatory Authority” means any of the FDA, DEA, parallel state or local Governmental Authorities, and their foreign counterparts.

 

“Required Lenders” means Lenders having (a) more than 60% of the Term Loan Commitments of all Lenders, or (b) if such Term Loan Commitments have expired or been terminated, more than 60% of the aggregate outstanding principal amount of the Term Loans; provided, however, that so long as a party that is a Lender hereunder on the Closing Date does not assign any portion of its Term Loan Commitment or Term Loan, the term “Required Lenders” shall include such Lender.  For purposes of this definition only, a Lender shall be deemed to include itself, and any Lender that is an Affiliate or Approved Fund of such Lender.

 

“Required Permit” means a Permit issued or required under Laws applicable to the business of any Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services under Laws applicable to the business of Borrower or any of its Subsidiaries or any Drug Application (including without limitation, at any point in time, all licenses, approvals and permits issued by the FDA or any other Regulatory Authority necessary for the testing, manufacture, marketing or sale of any Product by any Borrower or any of its Subsidiaries as such activities are being conducted by such Borrower or Subsidiary with respect to such Product at such time); provided that “Required Permits” shall not include state and local licenses and permits generally required in the Ordinary Course of Business and not specific to the line(s) of business in which any Borrower or any of its Subsidiaries is engaged.

 

“Requirement of Law” means as to any Person, the organizational or governing documents of such Person, and any Law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case 

 

  

50

  

 

applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.

 

“Responsible Officer” means any of the President and Chief Executive Officer or Chief Financial Officer of Borrower.

 

“Secured Promissory Note” has the meaning given it in Section 2.7.

 

“Secured Promissory Note Record” means a record maintained by each Lender with respect to the outstanding Obligations and credits made thereto.

 

“Securities Account” means any “securities account”, as defined in the Code, with such additions to such term as may hereafter be made.

 

“Subordinated Debt” means indebtedness incurred by Borrower subordinated to all of Borrower’s now or hereafter indebtedness to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Agent and the Lenders entered into between Agent, Borrower and the other creditor), on terms acceptable to Agent and the Lenders.

 

“Subsidiary” means, with respect to any Person, any Person of which more than 50.0% of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or one or more of Affiliates of such Person.

 

“Term Loan” or “Term Loans” has the meaning given it in Section 2.2(a).

 

“Term Loan Commitment” means, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on Schedule 1.”Term Loan Commitments” means the aggregate amount of such commitments of all Lenders.

 

“Tranche Two Eligibility Date” means the date on which Agent determines that Borrower has satisfied the following condition precedent to an advance in respect of Tranche Two:  Borrower has announced final results from the present ongoing Phase II study for PMX-60056 or PMX-30063, which data results in Borrower having regulatory clearance to proceed with additional Phase 2 or Phase 3 clinical studies; provided that, in Agent’s sole and absolute discretion, such condition precedent may be waived.

 

“Transfer” has the meaning given it in Section 7.1.

 

“Warrants” means those certain Warrants to Purchase Stock dated as of the Closing Date executed by Borrower in favor of each Lender or such Lender’s Affiliates.

 

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]

 

  

51

  

(Signature Page to Loan and Security Agreement)

IN WITNESS WHEREOF, intending to be legally bound, and intending that this Agreement constitute an agreement executed under seal, the undersigned have duly executed this Agreement under seal as of the Closing Date.

 

	
BORROWER:

 

	
POLYMEDIX, INC., a Delaware corporation

By:           /s/ Edward F. Smith (SEAL)

Name:           Edward F. Smith

Title:             Vice President, Chief Financial

      Officer and Secretary

	  	
POLYMEDIX PHARMACEUTICALS, INC., a Delaware corporation

By:           /s/ Edward F. Smith (SEAL)

Name:           Edward F. Smith

Title:             Vice President, Chief Financial

      Officer and Secretary

  

  

  

(Signature Page to Loan and Security Agreement)

	
AGENT:

	
MIDCAP FINANCIAL SBIC, LP,

a Delaware limited partnership

By:  Midcap Financial SBIC GP, LLC

By:             /s/ Joshua Groman (SEAL)

Name:             Joshua Groman, Ph.D.

Title:              Authorized Signatory

 

  

  

  

(Signature Page to Loan and Security Agreement)

	
LENDERS:

	
MIDCAP FINANCIAL SBIC, LP,

a Delaware limited partnership

By:  Midcap Financial SBIC GP, LLC

By:             /s/ Joshua Groman (SEAL)

Name:             Joshua Groman, Ph.D.

Title:              Authorized Signatory

 

 

  

  

  

EXHIBITS  AND SCHEDULES

 

EXHIBITS 

 

	
Exhibit A

	
Collateral

	
Exhibit B

	
Form of Loan Payment / Advance Request Form

	
Exhibit C

	
Form of Compliance Certificate

	
Exhibit D

	
Form of Secured Promissory Note

	
Exhibit E

	
Form of Warrant

	
Exhibit F

	
SBA Form 468

SCHEDULES

 

	
Schedule 1

	
Lenders and Commitments

	
Schedule 5.1

	
Organizational Information

	
Schedule 5.2

	
Collateral Disclosures

	
Schedule 5.3

	
Litigation

	
Schedule 5.11

	
Products and Required Permits

	
Schedule 6.12

	
Post-Closing Obligations

	
Schedule 7.4

	
Indebtedness

	
Schedule 7.7

	
Investments

  

  

  

EXHIBIT A

 

COLLATERAL

 

 

The Collateral consists of all assets of Borrower, including all of Borrower’s right, title and interest in and to the following personal property:

 

(a)           all goods, Accounts (including health-care insurance receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, investment accounts, commodity accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), IP Proceeds, securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and

 

(b)           all Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

 

Notwithstanding the foregoing, the Collateral shall not include any Intellectual Property of any Loan Party, whether now owned or hereafter acquired, except to the extent that it is necessary under applicable law to have a Lien and security interest in any such Intellectual Property in order to have a perfected Lien and security interest in and to IP Proceeds (defined below), and for the avoidance of any doubt, the Collateral shall include, and Agent shall have a Lien and security interest in, (i) all IP Proceeds, and (ii) all payments with respect to IP Proceeds that are received after the commencement of a bankruptcy or insolvency proceeding.  The term “IP Proceeds” means, collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments, insurance claims, and other revenues, proceeds or income, arising out of, derived from or relating to any Intellectual Property of any Loan Party, and any claims for damage by way of any past, present or future infringement of any Intellectual Property of any Loan Party (including, without limitation, all cash, royalty fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on behalf of a Loan Party and the proceeds from the sale, licensing or other disposition of all or any part of, or rights in, any Intellectual Property by or on behalf of a Loan Party).

 

Pursuant to the terms of a certain negative pledge arrangement with Agent and Lenders, Borrower has agreed not to encumber any of its Intellectual Property without Agent’s and Lenders’ prior written consent.

 

 

 

  

  

  

EXHIBIT B

 

LOAN PAYMENT/ADVANCE REQUEST FORM

 

Deadline is Noon E.S.T.

 

Date: __________________, 201__

 

	
LOAN PAYMENT:

	
From Account #________________________

    (Deposit Account #)

	
To Account #__________________________

(Loan Account #)

	
Principal $___________________________ and/or Interest ____________________________

	
Authorized Signature:                                                                     

	
Phone Number:                                                                     

	
Print Name/Title:                                                                    

	  

	
Loan Advance:

	
Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire.

	
From Account #

(Loan Account #)

	
To Account #                                                              

(Deposit Account #)

	
Amount of Advance $                                                              

	
All Borrower’s representations and warranties in the Loan and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date:

	
Authorized Signature:

	
Phone Number:                                                              

	
Print Name/Title:

	  

	
Outgoing Wire Request:

	
Complete only if all or a portion of funds from the loan advance above is to be wired.

	
Beneficiary Name:

	
Amount of Wire: $                                                              

	
Beneficiary Lender:

	
Account Number:                                                              

	
City and State:

	  
	
Beneficiary Lender Transit (ABA) #:

(For International Wire Only)

	
Beneficiary Lender Code (Swift, Sort, Chip, etc.):

	
Intermediary Lender:

	
Transit (ABA) #:                                                              

	
For Further Credit to:

	
Special Instruction:

	
By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me.

	
Authorized Signature:

	
2nd Signature (if required):                                                              

	
Print Name/Title:

	
Print Name/Title:                                                              

	
Telephone #:

	
Telephone #:                                                              

  

  

  

EXHIBIT C

 

COMPLIANCE CERTIFICATE

 

	
TO:

	
MidCap Financial SBIC, LP, as Agent

	
FROM:

	
_________________________________

	
DATE:

	
________________, 201__

The undersigned authorized officer of [PolyMedix, Inc.] (“                                                                                                                     ”) certifies that under the terms and conditions of the Loan and Security Agreement between PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc., Agent and the Lenders (the “Agreement”):

 

(1)           Borrower is in complete compliance with all required covenants for the month ending _______________, 201__, except as noted below;

 

(2)           there are no Events of Default;

 

(3)           all representations and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date;

 

(4)           Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.8 of the Agreement;

 

(5)           no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Agent; and

 

(6)           [an updated Schedule 5.2(d) is attached hereto describing any new Registered Intellectual Property that has been acquired and/or developed and any other material change in Borrower’s Material Intellectual Property, in each case since the date of the last Compliance Certificate] OR [no new Registered Intellectual Property has been acquired and/or developed, nor has there been any material change in Borrower’s Material Intellectual Property since the date of the last Compliance Certificate]

 

Attached are the required documents supporting the certifications set forth in this Compliance Certificate.  The undersigned certifies, in his/her capacity as an officer of the Borrower, that these are prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes.  The undersigned acknowledges, in his/her capacity as an officer of Borrower, that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered.  Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.

 

	
Please indicate compliance status by circling Yes/No under “Complies” column.

	  
	
Reporting Covenant

 

	
Required

	
Complies

	
Monthly Financial Statements

	
Monthly within 30 days

	
Yes

	
No

	
Audited Financial Statements

	
Annually within 120 days after FYE

	
Yes

	
No

	
Board Approved Projections

	
Annually within 30 days after FYE

	
Yes

	
No

	
Compliance Certificate

	
Monthly within 30 days

	
Yes

	
No

The following are the exceptions with respect to the certification above:  (If no exceptions exist, state “No exceptions to note.”)

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

 

	
POLYMEDIX, INC.

By:                                                              

Name:                                                              

Title:                                                              

	
AGENT USE ONLY

Received by:                                                              

authorized signer

Date:                                                              

Verified:                                                              

authorized signer

Date:                                                              

	  	
Compliance Status:

	
Yes

	
No

  

  

  

EXHIBIT D

 

SECURED PROMISSORY NOTE

 

  

  

  

EXHIBIT E

 

WARRANT

 

  

  

  

SCHEDULE 1

 

LENDERS AND COMMITMENTS

 

	
Lender

	
Term Loan Commitment

	
Commitment Percentage

	
MidCap Financial SBIC, LP

	
$12,000,000

	
100%

	  	  	  
	
TOTAL

	
$12,000,000

	
100%

  

  

  

SCHEDULE 5.1

 

ORGANIZATIONAL INFORMATION

 

Legal Name of Borrower:

 

Type of Legal Entity:

 

State of Organization:

 

Organizational Identification Number:

 

Tax Identification Number:

 

Principal Place of Business:

 

Legal Name of Borrower:

 

Type of Legal Entity:

 

State of Organization:

 

Organizational Identification Number:

 

Tax Identification Number:

 

Principal Place of Business:

 

  

  

  

SCHEDULE 5.2(A)

 

COLLATERAL ACCOUNTS

 

  

  

  

SCHEDULE 5.2(D)

 

INTELLECTUAL PROPERTY AND LICENSE AGREEMENTS

 

	
[APPLIES TO ALL Intellectual Property and License Agreements]

	
Borrower

	
Name / Identifier of IP or License

	
Type of IP (e.g., patent, TM, ©, mask work) or License Agreement

	
Expiration Date

(if a License, expiration of License and Licensed Property)

	  	  	  	  
	  	  	  	  
	  	  	  	  
	  	  	  	  
	  	  	  	  

	
[APPLIES TO License Agreements ONLY]

	
Name and Address of Licensor

	
Name and Date of License Agreement

	
Exclusive License? (Yes/No)

	
Restrictions to grant a lien, assign or sublicense?

(Yes/No)

	
Default or Termination affect Agent’s ability to sell or assign?

(Yes/No)

	  	  	  	  	  
	  	  	  	  	  
	  	  	  	  	  
	  	  	  	  	  
	  	  	  	  	  
	  	  	  	  	  

  

  

  

SCHEDULE 5.2(E)

 

LOCATION OF COLLATERAL

 

  

  

  

SCHEDULE 5.3

 

LITIGATION

 

  

  

  

SCHEDULE 5.11

 

PRODUCTS AND REQUIRED PERMITS

 

  

  

  

SCHEDULE 6.12

 

POST CLOSING OBLIGATIONS

 

Borrowers shall satisfy and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or before the date indicated below, all to the satisfaction of Agent in its sole and absolute discretion:

 

1.

 

Borrower’s failure to complete and satisfy any of the above obligations on or before the date indicated above, or Borrower’s failure to deliver any of the above listed items on or before the date indicated above, shall constitute an immediate an automatic Event of Default.

 

  

  

  

SCHEDULE 7.4

 

INDEBTEDNESS AS OF THE CLOSING DATE

 

  

  

  

SCHEDULE 7.7

 

INVESTMENTS AS OF THE CLOSING DATE

 

  

  

  

 

TABLE OF CONTENTS

 

Page

 

	
1.

	
ACCOUNTING AND OTHER TERMS 

	
1

 

	
2.

	
LOAN AND TERMS OF PAYMENT 

	
1

 

	
  

	
2.1

	
Promise to Pay 

	
1

 

	
  

	
2.2

	
Term Loans 

	
1

 

	
  

	
2.3

	
Payment of Interest on the Credit Extensions 

	
2

 

	
  

	
2.4

	
Fees and Expenses 

	
4

 

	
  

	
2.5

	
Additional Costs 

	
4

 

	
  

	
2.6

	
Payments and Taxes 

	
4

 

	
  

	
2.7

	
Secured Promissory Notes 

	
5

 

	
  

	
2.8

	
Issuance of Warrants to Lenders 

	
5

 

	
  

	
2.9

	
SBIC Acknowledgement 

	
5

 

	
3.

	
CONDITIONS OF LOANS 

	
5

 

	
  

	
3.1

	
Conditions Precedent to Initial Credit Extension 

	
5

 

	
  

	
3.2

	
Conditions Precedent to all Credit Extensions 

	
6

 

	
  

	
3.3

	
Covenant to Deliver 

	
7

 

	
  

	
3.4

	
Procedures for Borrowing 

	
7

 

	
4.

	
CREATION OF SECURITY INTEREST 

	
7

 

	
  

	
4.1

	
Grant of Security Interest 

	
7

 

	
  

	
4.2

	
Authorization to File Financing Statements 

	
8

 

	
5.

	
REPRESENTATIONS AND WARRANTIES 

	
8

 

	
  

	
5.1

	
Due Organization, Authorization: Power and Authority 

	
8

 

	
  

	
5.2

	
Collateral 

	
9

 

	
  

	
5.3

	
Litigation 

	
10

 

	
  

	
5.4

	
No Material Deterioration in Financial Condition; Financial Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   10

 

	
  

	
5.5

	
Solvency 

	
10

 

	
  

	
5.6

	
Regulatory Compliance 

	
10

 

	
  

	
5.7

	
Subsidiaries; Investments 

	
11

 

	
  

	
5.8

	
Tax Returns and Payments; Pension Contributions 

	
11

 

  

i

  

 

	
  

	
5.9

	
Use of Proceeds 

	
12

 

	
  

	
5.10

	
Full Disclosure 

	
12

 

	
  

	
5.11

	
Regulatory Developments 

	
12

 

	
6.

	
AFFIRMATIVE COVENANTS 

	
13

 

	
  

	
6.1

	
Organization and Existence; Government Compliance 

	
13

 

	
  

	
6.2

	
Financial Statements, Reports, Certificates 

	
13

 

	
  

	
6.3

	
Inventory; Returns 

	
15

 

	
  

	
6.4

	
Taxes; Pensions 

	
15

 

	
  

	
6.5

	
Insurance 

	
15

 

	
  

	
6.6

	
Operating Accounts 

	
16

 

	
  

	
6.7

	
Protection of Intellectual Property Rights 

	
16

 

	
  

	
6.8

	
Litigation Cooperation 

	
16

 

	
  

	
6.9

	
Notices of Litigation and Default 

	
16

 

	
  

	
6.10

	
Creation/Acquisition of Subsidiaries 

	
17

 

	
  

	
6.11

	
Further Assurances 

	
17

 

	
  

	
6.12

	
Post-Closing Obligations 

	
17

 

	
7.

	
NEGATIVE COVENANTS 

	
17

 

	
  

	
7.1

	
Dispositions 

	
18

 

	
  

	
7.2

	
Changes in Business, Management, Ownership or Business Locations 

	
18

 

	
  

	
7.3

	
Mergers or Acquisitions 

	
18

 

	
  

	
7.4

	
Indebtedness 

	
18

 

	
  

	
7.5

	
Encumbrance 

	
18

 

	
  

	
7.6

	
Maintenance of Collateral Accounts 

	
18

 

	
  

	
7.7

	
Distributions; Investments 

	
19

 

	
  

	
7.8

	
Transactions with Affiliates 

	
19

 

	
  

	
7.9

	
Subordinated Debt 

	
19

 

	
  

	
7.10

	
Compliance 

	
19

 

	
  

	
7.11

	
Compliance with Anti-Terrorism Laws 

	
19

 

  

ii

  

 

	
8.

	
EVENTS OF DEFAULT 

	
20

 

	
  

	
8.1

	
Payment Default 

	
20

 

	
  

	
8.2

	
Covenant Default 

	
20

 

	
  

	
8.3

	
Material Adverse Change 

	
20

 

	
  

	
8.4

	
Attachment; Levy; Restraint on Business 

	
20

 

	
  

	
8.5

	
Insolvency 

	
21

 

	
  

	
8.6

	
Other Agreements 

	
21

 

	
  

	
8.7

	
Judgments 

	
21

 

	
  

	
8.8

	
Misrepresentations 

	
21

 

	
  

	
8.9

	
Subordinated Debt 

	
21

 

	
  

	
8.10

	
Governmental Approvals 

	
21

 

	
  

	
8.11

	
Criminal Proceeding 

	
22

 

	
  

	
8.12

	
Lien Priority 

	
22

 

	
  

	
8.13

	
Change in Control 

	
22

 

	
  

	
8.14

	
Withdrawals, Recalls, Adverse Test Results and Other Matters 

	
22

 

	
9.

	
RIGHTS AND REMEDIES 

	
22

 

	
  

	
9.1

	
Rights and Remedies 

	
22

 

	
  

	
9.2

	
Power of Attorney 

	
24

 

	
  

	
9.3

	
Protective Payments 

	
24

 

	
  

	
9.4

	
Application of Payments and Proceeds 

	
24

 

	
  

	
9.5

	
Liability for Collateral 

	
25

 

	
  

	
9.6

	
No Waiver; Remedies Cumulative 

	
25

 

	
  

	
9.7

	
Demand Waiver 

	
26

 

	
  

	
9.8

	
Borrower Liability 

	
26

 

	
10.

	
NOTICES 

	
26

 

	
11.

	
CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

	
27

 

	
12.

	
GENERAL PROVISIONS 

	
28

 

	
  

	
12.1

	
Successors and Assigns 

	
28

 

  

iii

  

 

	
  

	
12.2

	
Indemnification 

	
29

 

	
  

	
12.3

	
Time of Essence 

	
29

 

	
  

	
12.4

	
Severability of Provisions 

	
29

 

	
  

	
12.5

	
Correction of Loan Documents 

	
29

 

	
  

	
12.6

	
Integration 

	
29

 

	
  

	
12.7

	
Counterparts 

	
30

 

	
  

	
12.8

	
Survival 

	
30

 

	
  

	
12.9

	
Confidentiality 

	
30

 

	
  

	
12.10

	
Right of Set Off 

	
30

 

	
  

	
12.11

	
[Reserved] 

	
31

 

	
  

	
12.12

	
Amendments 

	
31

 

	
  

	
12.13

	
Publicity 

	
32

 

	
  

	
12.14

	
No Strict Construction 

	
32

 

	
13.

	
AGENT 

	
32

 

	
  

	
13.1

	
Appointment and Authorization of Agent 

	
32

 

	
  

	
13.2

	
Delegation of Duties 

	
33

 

	
  

	
13.3

	
Liability of Agent 

	
33

 

	
  

	
13.4

	
Reliance by Agent 

	
33

 

	
  

	
13.5

	
Notice of Default 

	
34

 

	
  

	
13.6

	
Credit Decision; Disclosure of Information by Agent 

	
34

 

	
  

	
13.7

	
Indemnification of Agent 

	
34

 

	
  

	
13.8

	
Agent in its Individual Capacity 

	
35

 

	
  

	
13.9

	
Successor Agent 

	
35

 

	
  

	
13.10

	
Agent May File Proofs of Claim 

	
36

 

	
  

	
13.11

	
Collateral and Guaranty Matters 

	
36

 

	
  

	
13.12

	
Cooperation of Borrower 

	
37

 

	
14.

	
DEFINITIONS 

	
37

 

  

iv

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]